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Abstract 
 
Introduction 
The greatest challenge facing the success of orthopaedic implants is improving their 
fixation to bone to enhance their longevity. Bone marrow stromal cells (BMSC), are a 
population of plastic-adherent cells derived from the bone marrow. The main 
hypothesis of this thesis is that viable BMSC can be applied to implants using a fibrin 
glue-spray system; and increase bone formation adjacent to the implants and improve 
bone-implant contact. 
 
Methods 
The experiments were undertaken in a large animal model. Four scenarios were tested  
1) The ability of BMSC to improve implant fixation using models of total hip 
replacement, massive endoprosthetic replacement and bone defect around pins. 
2) The effect of varying cell dosages of BMSC in their ability to produce new bone 
and improve bone implant contact. 
3) The effect of differentiating the BMSC along the osteogenic pathway in their ability 
to produce new bone and improve bone implant contact. 
4) The effect of using semi-permeable barriers around BMSC sprayed on implants to 
prevent cell migration  
 
Results 
1) BMSC sprayed on the surface of implants resulted in increased bone formation 
in the total hip replacement, massive endoprosthetic replacement and bone defect 
around pin models. 
2) Bone formation was higher with osteogenic 10x106 BMSC (112.67 ± 30.75 
 3 
mm
2
) compared to osteogenic 2x10
6 
BMSC (76.84 ± 2.25 mm
2
). No significant 
difference was noted in bone formation between undifferentiated 1x10
5
 BMSC 
(30.76 ± 9.43%) and undifferentiated 10x10
6 
BMSC (28.27 ± 14.64%). 
3) Osteogenic differentiated 10x106 BMSC (112.67 ± 30.75 mm2) produced more 
bone than undifferentiated 10x10
6 
BMSC (58.22 ± 17.22 mm
2
).  
4) Using semipermeable barriers resulted in significantly increased bone formation 
when undifferentiated 1x10
5
 BMSC (61.32 ± 6.94% vs 30.76 ± 9.43%) or 
undifferentiated 10x10
6 
BMSC (57.46 ± 4.39% vs 28.27 ± 14.64%) was used. 
This difference was not noted when osteogenic differentiated 10x10
6 
BMSC was 
used. 
 
The experiments confirm that viable BMSC can be successfully isolated from bone 
marrow aspiration, differentiated along the osteogenic pathway and sprayed on the 
surface of various orthopaedic implants to improve bone-implant contact.  
 
Conclusion 
This technique of using BMSC may be an ideal alternative to improve 
osseointegration of implants in challenging clinical scenarios with deficient bone 
stock. 
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The use of implants has revolutionised orthopaedic surgery. One of the greatest 
challenges facing the success of orthopaedic implants is improving their fixation to 
bone to enhance longevity.  Other challenges include; selection of the most appropriate 
bearing surface; restoring biomechanics by accurate implant positioning and dealing 
with inadequate bone stock in revision surgery or following resection of bone for tumor. 
The following chapters describe the use of bone marrow stromal cells (BMSC) 
suspended in fibrin glue and sprayed on the surface of implants to enhance their 
fixation. The experiments were undertaken in a large animal model. The use of 
autologous BMSC suspended in fibrin glue to produce new bone and enhance implant 
fixation was investigated first. Following this the effects of various concentrations of 
BMSC and their interaction with a semi-permeable membrane [polytertrafluroethylene 
(PTFE)] used for guided bone regeneration was studied. Finally, the role of BMSC 
differentiated in an osteogenic supplemented media was studied. 
The main hypothesis of this thesis is that the longevity of orthopaedic metal implants 
can be increased by intra-operatively coating their surface with autologous BMSC-
fibrin suspension. 
This introduction provides an overview of the use of prosthetic replacements in various 
challenging clinical situations and their modes of failure. The experimental and clinical 
use of bone marrow stromal cells (BMSC) is reviewed as well as the use of alternative 
sources to BMSC. 
 
1.1 Total hip replacements 
 
The biggest landmark in total hip replacement (THR) came with the development in the 
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1960s of the low friction arthroplasty concept by Sir John Charnley (Charnley, 1972). 
After first using a polytetrafluoroethylene (PTFE) cup, Charnley used the relatively low 
friction couple between the high density polyethylene for the acetabulum and stainless 
steel for the femoral head components. The use of these materials was a major factor in 
reducing wear. His implants were also designed to have small metal heads, 22mm in 
diameter, conferring less torque whilst providing a thick plastic cup. Although Charnely 
used acrylic bone cement to fix his implants to the bone, currently both cemented and 
cementless fixation options of total hip replacements are available. The combinations of 
bearing surfaces available are: metal on polyethylene, such as a cobalt-chrome head 
with ultra high molecular weight polyethylene (UHMWPE) or more recently cross 
linked polyethelene liners; metal-on-metal, for instance a cobalt-chrome femoral head 
coupled with a cobalt-chrome liner, or ceramic-on-ceramic and ceramic on polyethelene 
combinations of head and liner (Heisel et al., 2004).  
 
1.2 Challenges facing the future of THRs 
 
Total hip replacement (THR) is regarded as one of the most successful advances in 
modern orthopaedic surgery, with over a 90% clinical success rate at 10 years (Bellamy 
et al., 1988).  In the UK, 50,000 total hip replacements (1 million worldwide) are 
carried out each year at a cost to the NHS of more than £140 million per annum, an 
increase of 18% since 1991 (Report by the controller and Auditor General, 2000).  This 
number is set to increase by up to 50% by 2026 due to demographic changes in the 
population (Birrell et al., 1999).  Forty percent of surgeons are now willing to carry out 
this procedure on young and active patients; which contributes to the growing 
requirement for total hip replacement surgery (Dixon et al., 2004).  Younger patients 
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with high expectations not only live longer but place high demands on their joint 
replacements.  The increasing number of total hip replacements, especially in the young, 
has led to a 100% increase in revision surgery due to implant failure since 1991.  In the 
UK, approx. 9,000 (18%) of all hip surgery procedures are now revisions (Dixon et al., 
2004).  The American Academy of Orthopaedic Surgeons (AAOS) has estimated that 
the number of revision total hip arthroplasties will continue to rise at a rate of 20% to 
30% per year over the next three decades (Frankowski, 2002). The average unit cost of 
revision surgery according to the Health and Social Care Information Centre 
(www.doh.gov.uk) is £6,568.  Thus on average, the NHS spends £59.1 million on costs 
associated with revising loose hip components. 
 
Revision hip procedures cost more to perform than primary procedures (average unit 
cost =£4,744.00).  Recent studies have reported that the mean operative time, the 
estimated blood loss, the complication rate and mean hospital stay are all longer for 
patients undergoing revision surgery when compared with primary hip surgery (Bozic et 
al.), (Crowe et al., 2003).  In comparison with primary procedures the success of 
revision hip replacements are reduced.  Approximately 25% - 50% of revision 
procedures will fail and patients with extensive bone loss often face multiple 
problematic and unsuccessful revision hip replacements as a result of inadequate 
femoral and acetabular component fixation (Sporer and Paprosky, 2005), 
(Krishnamurthy et al., 1997).  The survivorship of these prostheses is reduced with each 
operation and bone loss is further exacerbated (Malchau et al., 1993), (Slooff et al., 
1998).  Thus the annual NHS expenditure is increased.  Stable fixation and successful 
clinical outcomes are dependent on bony support for the implant.  Regeneration of bone 
adjacent to the implants would reduce component failure.  Aseptic loosening of the 
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acetabular component is the major cause of failure in total hip replacement surgery 
(Berry et al., 2002), (Wroblewski and Siney, 1993).   
 
1.3 Osteolysis in the failure of THRs 
 
Wear particle induced osteolysis often results in a decrease in the bone stock which is 
required for implant fixation in revision hip replacements (Harris, 1995), (Cooper et al., 
1992). The mechanism of osteolysis is triggered by particles of metal, cement or 
polyethylene that are released when surfaces of the implant articulate with one another. 
These particles are able to travel along small spaces between the implant interfaces, 
such as the stem-cement interface. When they come into contact with biological tissues 
these particles become engulfed by inflammatory cells, such as macrophages and giant 
cells. This activates macrophages which release bone resorbing mediators such as 
interleukin-1 (IL-1) and tumour necrosis factor  alpha (TNF-a), an osteoclast activating 
cytokine stimulating osteoclasts to differentiate from monocytes and resorb bone 
(Athanasou, 1996). There is evidence that macrophages contribute directly to osteolysis 
by differentiation into osteoclasts. Macrophages have been isolated from periprosthetic 
tissues and differentiated into osteoclasts in vitro (Sabokbar et al., 1997). The RANK-
RANKL-OPG pathway constitutes a basic control network that regulates bone 
remodelling.  This is also the case in osteolysis where bone cells such as osteoblasts and 
osteoclasts regulate bone turnover. The trans-membrane receptor, Receptor Activator of 
Nuclear factor kappa B ligand (RANKL), is expressed on the surface of pre-osteoblastic 
cells which binds to Receptor Activator of Nuclear factor kappa B (RANK) on 
osteoclast precursors. This allows differentiation and activation of cells of the 
macrophage/monocyte lineage into osteoclasts and, thus, leads to resorption.   The 
Chapter 1 
 17 
ability of pre-osteoblasts to support osteoclastic development is lost during 
differentiation down the osteoblastic pathway as RANKL is downregulated and 
osteoprotegerin (OPG), an osteoclast inhibitor produced by the osteoblasts, is increased. 
It would be counterproductive for the mature osteoblasts to stimulate osteoclasts to 
destroy osteoid they have just laid down (Khosla, 2001). There is also evidence that 
osteolysis is triggered by hydrostatic pressure around hip components after hip 
replacements. In a study comparing the resorptive effect of cement particles and 
pressure in a rat tibial diaphysis, the osteolytic process was influenced more by 
biomechanical stimuli than the cement particles (Skoglund and Aspenberg, 2003). The 
most aggressive form of osteolysis is described clinically as erosive, inflamed bone 
resorption, where a fibrous membrane eventually surrounds the loosened implant. This 
can be observed in cemented acetabular components. However, periprosthetic osteolysis 
is also prevalent in cementless femoral components despite excellent femoral fixation at 
five years (Cooper et al., 1992). This indicates that despite improvements in fixation 
techniques and optimisation of surface characteristics, such as implant coatings of HA 
(Coathup et al., 2005), there is still debris release due to wear (Amstutz et al., 1992). 
Although it may be possible to minimise wear debris release, it is likely that bone stock 
will be depleted by osteolysis for the foreseeable future. 
 
1.4 Massive Endoprosthetic Replacements 
 
Another common clinical scenario where achieving bone implant osseointegration is 
crucial is when using endoprosthetic replacements following bone resection for tumor.  
A combination of factors such as early detection of tumours, the increased use of 
chemotherapy, radiotherapy, and improved surgical techniques has resulted in increased 
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survival of bone tumor patients (Capanna et al., 1994); (Cannon, 1997); (Grimer et al., 
1999); (Horowitz et al., 1993). Adjuvant chemotherapy (given post-operatively) has 
reduced the probability of recurrence and/or metastases (Eckardt et al., 1991b); (Uchida 
et al., 1997). The surgical options available for the management of the segmental defect 
created during tumour excision, in order to preserve the limb are: arthrodesis with 
auto/allograft; vascularized fibular autograft, resection and reinsertion of bone after 
sterilization; and arthroplasty using either auto/allograft, synthetic graft or massive 
endoprostheses, including extendible prostheses for growing patients (Schindler et al., 
1997); (Unwin et al., 1996). 
Routine use of bone graft has its limitations in everyday clinical practice. It is frequently 
difficult to obtain sufficient amounts of autograft for bone tumour resection sites. Donor 
site morbidity can be an issue (Abudu et al., 1996). Allografts suffer similar problems in 
terms of supply, disease transfer from donor to patient, graft failure and fracture, as well 
as issues with non-union of the graft to the host bone (Gebhardt et al., 1991).  
The options excluding the use of bone grafts following large segment bone resections 
are amputation or endoprosthetic replacements. The latter have the obvious advantage 
of preserving the function and aesthetics of the original limb, while allowing immediate 
post-operative weight bearing (Grimer et al., 1999). Studies have attempted to 
determine the long-term effects of amputation and endoprosthetic replacement on 
tumour recurrence, functionality of the limb post-replacement and patient satisfaction. 
Results showed that limb-salvage procedures result in the same rate of disease-free 
survival as amputations after 10 years, with no significant difference in patient 
satisfaction in most cases (Rougraff et al., 1994); (Sugarbaker et al., 1982); 
(Weddington et al., 1985). Some studies state a patient preference for limb salvage over 
amputation (Harris et al., 1990), and a study by (Grimer et al., 1999) indicated that 
endodoprosthetic reconstructions are more cost effective than amputation.  
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The massive implants for limb-salvage surgery are either custom-made or modular 
(Cannon, 1997) and generally use stems that are cemented into the intramedullary 
canals with polymethylmethacrylate (PMMA). Uncemented stems are also used (Blunn 
et al., 2000); (Capanna et al., 1994). An alternative to the use of intramedullary stems is 
triplate fixation, where extracortical fixation can be used if there has been a large 
resection, and an insufficient amount of bone remains in which to cement an implant 
(Coathup et al., 2000); (Cobb et al., 2005). Femoral or tibial endoprostheses may also 
include a knee joint replacement when the bone tumour has spread to the knee or if 
there is possible contamination of the joint or synovium, and en bloc resection of the 
joint is required (Sim and Chao, 1979); (Walker et al., 1981).  
 
1.4.1 Failure of massive endoprosthetic replacements 
When compared with the success of joint replacements massive implants are not as 
successful (Blunn et al., 2000). The Swedish Hip registry found that the survival rate of 
total hip arthroplasties (THAs) over a ten-year period is 92% (Malchau et al., 2005). By 
comparison, a ten-year follow up study of massive implants with cemented 
intramedullary stems found that 93.8% of proximal femoral, 67.4% of distal femoral 
and 58% of proximal tibial prostheses survived ten years (Unwin et al., 1996). (Scales et 
al., 1984) investigated the causes of failure for Stanmore cemented massive implants in 
the 1980's and found that 5.4% of all endoprosthetic reconstructions resulted in 
infection, 2.7% resulted in implant fracture, and 1.9% failed due to aseptic loosening. 
Infection was reported to be more common in primary massive endoprosthetic 
replacements than with conventional joint replacements (Malawer and Chou, 1995). 
(Capanna et al., 1994) found that the infection rate of distal femoral replacements, using 
the Kotz modular femoral and tibial resection system (KMFTR) was highest when most 
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or all of the rectus and vasti muscles had been excised (Capanna et al., 1994). Infection 
has been a major concern for proximal tibial replacements. Bradish et al. (1987) 
reported a 7.5% infection rate in distal femoral replacements; whereas Roberts et al., 
(1991) found that, in 135 distal femoral replacements, 6.8% of all implants suffered 
from infection, whereas 6% failed due to aseptic loosening. A study by the Royal 
Orthopaedic Hospital in Birmingham found that up to 13.8% of proximal tibial 
reconstructions performed between 1977 and 1988 became infected in the first five 
years (Grimer et al., 1999). In 1995, (Malawer and Chou, 1995) reported a high rate of 
infection with proximal tibial replacements. Modern surgical techniques have reduced 
the overall infection rate suffered previously with this type of procedure. For example, 
in proximal tibial replacements, retention or replacement of lost musculature around the 
knee by use of a medial gastrocnemius flap has reduced the above-mentioned infection 
rate from 33% to 12% (Grimer et al., 1999). Improved surgical techniques that reduce 
incidences of infection and improved implant design have reduced the rate of implant 
survival, so that aseptic loosening is now considered the major cause of failure of 
cemented massive implants (Ward et al., 1997). Although mechanical complications are 
the most common cause of implant failure, infection is the leading cause of both 
complication and amputation (Shehadeh et al., 2010). The risk of infection increases 
substantially with revision surgery. As patients may be immunocompromised and 
surgical procedures tend to be complex and prolonged, infection rates are higher than 
routine implant surgery.  
As a result of adjuvant chemotherapy, there has been an increase in the number of 
young limb salvage patients. This has affected the results of more recent studies, as the 
methods that were developed for salvaging low-grade lesions in older patients are now 
routinely used in younger more active patients with wider resections for larger, more 
aggressive tumours. A study looking at distal femoral replacements, found that between 
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1959-1980, the survival rate of proximal femoral replacements was 83 ± 8%, whereas 
from 1980-1991, the survival rate was reduced to 64 ± 27% (Cobb, 1991).                                                    
 
A study (Unwin et al., 1996) looking at the outcome of 1001 patients with 
endoprosthetic replacement, mostly as a result of osteosarcoma, osteoclastoma, and 
chondrosarcoma, showed that over a ten-year period, although 93.8% of proximal 
femoral replacements survived a ten-year period, only 67.4% of distal femoral 
replacements and 54.8% of proximal tibial implants survived. Seventy-one of the 1001 
patients (7%) required implant revisions for component loosening. The study also found 
that patients under 20 years of age with more than 60% of bone resected from the distal 
femur or proximal tibia had the worst prognosis for implant survival. The amount of 
bone resected is also associated with failure in proximal tibial replacements (Unwin et 
al., 1996). The long-term study of implant loosening by (Unwin et al., 1996) looking at 
493 distal femoral, 263 proximal femoral and 245 proximal tibial replacements, found a 
high incidence of aseptic loosening. 
Failure of the humeral prosthesis due to aseptic loosening is rare and is probably due to 
a lack of heavy weight bearing in that limb (Cannon, 1997). Uncemented implants, 
using the Kotz system, did not appear to show similar levels of aseptic loosening, 
although there were some cases of implant fracture and infection (Capanna et al., 1994). 
(Horowitz et al., 1993) reported a 25% failure of distal femoral and proximal tibial 
implants within the first five-years post-operatively in sarcoma patients. (Unwin et al., 
1996) comparing survival data on 668 Stanmore femoral replacements (221 proximal 
and 447 distal femoral implants), found that the success of proximal femoral 
replacements over ten years was 92%, whereas the survival of distal femoral 
replacements was 72% when loosening as the only mode of failure was considered. 
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Loosening in this study was defined as when an implant became unstable in the femur, 
whether it was due to infection, mechanical forces, or bone remodelling in any 
replacement that required revision or resulted in amputation of the limb (Unwin et al., 
1996). 
Diaphyseal femoral and tibial implants also have similar loosening rates. Abudu et al., 
(1996) reported approximately one-third of their diaphyseal implants failing due to 
symptomatic mechanical loosening. One mode of failure is thought to result from 
torsional forces caused by the use of a fixed hinge knee component in certain massive 
implants (Roberts et al., 1991); (Unwin et al., 1996). The use of a rotating hinge has 
reduced the rate of aseptic loosening (Unwin et al., 1996). However, this is not the only 
cause of aseptic loosening responsible for implant failure. 
Studies by Blunn et al. (2000) and Unwin et al. (1996) have detailed a possible 
mechanism for aseptic loosening. In the case of massive implants, an offset exists 
between the implant stem and the axis of the femur from the femoral head to the centre 
of the knee. This offset is thought to cause a bending moment within the cemented 
fixation. Due to the line of load this offset is more pronounced proximally on the femur 
than distally and, thus, stems that are cemented more proximally in the bone suffer from 
greater bending forces within the cement mantle. 
As distal femoral replacements have more proximal transection sites and subsequent 
cement fixation than proximal femoral implants, they have a greater offset to the axis of 
the longbone. This is also the case with lengthier tumour resection, where the upper 
stem may be placed more proximally in the bone. The increased force from the bending 
caused by this offset eventually causes a deterioration of the bone-cement interface, 
which slowly progresses from the transection site to the stem tip of the implant (Unwin 
et al., 1996). 
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Loosening begins with osteolysis adjacent to the implant shoulder (Blunn and Wait, 
1991), (Ward et al., 1997), which can occur within six months post-operatively. Over 
time, osteolysis is seen to progress along the bone-cement interface, and 
radiographically can be viewed as radolucent lines. 
Cobb (Cobb, 1991) reported a deterioration of the interface between bone and cement, 
which correlated with decreased function of the implant. There was a steady 
deterioration of the interface and there was only a 56% probability of a good interface 
eight years post-operatively. A study investigating telemetric data from a 42-year old 
patient with a distal femoral joint replacement compared the forces applied to the stem 
tip to those on the implant shaft. This data showed an increasing force at the stem tip 
over time with an increase in the stem tip-to-shaft force ratio of 25% to 63% over 23 
months (Taylor et al., 1997). Supporting histological analysis of growing patients with 
extendible prostheses, shows bone remodelling adjacent to prostheses near porotic bone, 
and the growth of fibrous tissue under the implant shoulder. However, it must also be 
noted that the authors mentioned a possible effect on remodelling by the blood supply, 
which is interrupted during surgery and implantation of a cemented prosthesis. A 
subsequent ingrowth of blood vessels into necrotic bone from the invading fibrous 
tissue at the transection site occurs (Blunn and Wait, 1991). In addition, poor cement 
interdigitation, which is affected by the amount of cancellous bone and shape of the 
intramedullary canal into which the implant stem is inserted, could possibly affect the 
outcome of these prostheses (Unwin et al., 1996).  This is an important point not only 
for massive implants but also during revision of femoral stems for THR as there is often 
sclerotic bone adjacent to the cement. Nevertheless, various methods have been 
employed to promote load transfer to the shaft of the prosthesis from the bone at the 
transection site in an attempt to prevent aseptic loosening. As the survival rate of 
patients is increasing, the long-term fixation of massive endoprostheses is of even 
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greater importance and it is possible that bone marrow stromal cells (BMSC) could play 
a role in biologically improving the fixation of these implants. 
Bone is dynamic, and responds to compressive and tensile forces by bone formation and 
resorption respectively. Wolff’s law, as first described by Julius Wolff in 1892, is the 
theory that mechanical stress determines bone structure, and that a change in stress can 
consequently result in changes in bone composition (Wolff 1892). Applying this theory 
to remodelling in cases of massive implants means that bone adjacent to massive 
implants change, because of the new compressive and tensile forces being applied.  This 
is because of the redistribution of loads due to the modulus of elasticity of the metal 
used. Thus, certain trends in bone growth around these implants can be seen. 
A common radiographic observation around massive implants, which may reflect the 
bending effect, is bone growth posteriorly and medially, whereas bone resorption is 
often seen anteriorly and laterally (Inglis and Walker, 1991); (Unwin et al., 1996). 
Inglis, et al. (1991) reported such a pattern of bone growth around massive proximal 
femoral replacements. In this survey, which analyzed both lateral and anteroposterior 
radiographs, it was postulated that cortical thickening in the areas experiencing 
compressive forces would form a "column" of bone, which would move down the 
implant with the pressure applied by adjacent muscles.  
When prostheses are cemented, the consequence is that the host bone is under a 
decreased load and the strain is reduced, causing resorption. This phenomenon is known 
as "stress shielding" (Huiskes, 1990). This change in load distribution to the metal 
implant and reduction of load experienced by surrounding bone, causes strain adaptive 
remodelling to take place according to Wolff’s law (Wolff 1892). 
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1.5 Hydroxyapatite for improving implant fixation 
 
In some patients, a pedicle of bone grows from the transection site around massive 
metal implants, often with an intervening fibrous tissue layer between the implant and 
new bone (Blunn and Wait, 1991). Integration of the implant into the host bone by 
ingrowth and attachment of this new bone is thought to promote better load transfer to 
the shaft rather than the stem tip preventing "underloading" (Inglis and Walker, 1991) 
of the collar and overloading of the cement mantle (Okada et al., 1988); (Sim and Chao, 
1979). One method that promotes this is the use of a collar on the implant shaft, at the 
transection site. These collars encourage bone to grow over and attach to the shaft of the 
prosthesis. Modern implant coatings try to augment the "bony bridge" by using porous 
titanium beads, bone graft, grooves and/or a hydroxyapatite coating (Blunn et al., 2000); 
(Chao and Sim, 1985), (Okada et al., 1988); (Ward et al., 1993). 
Hydroxyapatite (HA) is a biocompatible, resorbable, osteoconductive material that has 
been found to greatly enhance bone growth in both patients and animal models (Blunn 
et al., 2000); (Coathup et al., 2000); (D'Antonio et al., 1992); (Geesink, 1993). 
Osteoconductivity is the ability of a scaffold to promote osteoblast attachment and bone 
formation. In comparison, an osteoinductive scaffold encourages osteoblast precursor 
cells, such as BMSC, to attach and differentiate into active osteoblasts. Natural bone is 
an example of an osteoinductive material (Datta et al., 2006). Another property of 
scaffolds, osteogenicity, refers to the presence of osteoblasts or osteoblast precursor 
cells that deposit bone directly on the scaffold surface (Mizutani et al., 1990).  
Synthetic hydroxyapatite is a calcium phosphate ceramic that shares a similar chemical 
and crystallographic structure to natural hydroxyapatite, which is the main mineral 
component of bone (Engfeldt et al., 1953); (Jarcho, 1981). Although it has poor fatigue 
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properties, which prevents it from being a useful structural implant material, HA can be 
applied to metal surfaces using a plasma-spray technique. This provides an implant with 
osteoconductive properties while maintaining the mechanical properties of a metal 
implant (Geesink et al., 1988). The bonding of bone to HA-coated implants has been 
investigated previously in canines and was found to be very strong as a result of direct 
bonding of the material to bone (Geesink et al., 1988). As the HA is resorbed, released 
calcium and phosphate ions may also promote formation of a biological apatite layer, 
and thus promote osteoinduction (Kurioka et al., 1999); (Ozawa and Kasugai, 1996). 
However, concerns do exist about the stability of the metal implant-HA bond, in that it 
is non-permanent and may lead to wear particle production (Bloebaum et al., 1994). 
The use of grooved, porous, hydroxyapatite-coated collars has shown effective results in 
terms of bone ingrowth to the implant collars (Blunn et al., 2000). In the short-term 
follow-up reported by the authors (after more than 12 months), only one patient out of 
forty-four showed any signs of loosening, and a radiographic study showed no signs of 
radiolucency around the implant (Chao et al., 2004) and significantly improved 
extracortical bone growth around massive implants in patients by using a porous-coated 
collar augmented with autologous bone graft. Only one out of forty-three patients 
showed aseptic loosening after a mean of 9.7 years follow-up. The use of cementless 
fixation with proximal femoral components showed that the use of HA coincided with a 
more even distribution of bone growth around the implant when compared with control 
implants (Blunn et al., 2000).  
Compared to uncoated porous collars, hydroxyapatite-coated collars on distal femoral 
replacements appear to promote bone ingrowth in over 70% of cases. This ingrowth is 
negatively correlated to the extent of radiolucent lines on radiographs. Good bone 
formation into the HA-coated collars resulted in a decrease in the size and number of 
radiolucent lines around the intramedullary stem (Unwin, 2005), (Cobb, 1991). 
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As this uncoupling of load at the implant shoulder to the stem tip ultimately results in 
debonding and loosening of the implant (Unwin et al., 1996), strategies to prevent this 
initial uncoupling have been considered. Ideally, the use of a biocompatible material 
with an elastic modulus closer to that of cortical bone would prevent overloading of the 
stem tip. Recently, studies that have investigated more flexible materials have shown 
them to promote higher proximal shear stresses between the stem/cement and bone 
interface. This could result in debonding, micro-motion, and eventual loosening of the 
implant (Huiskes, 1990). 
One strategy to reduce aseptic loosening (Figure 1.1) has been to improve the fixation 
of the implant to the bone by improving the osseous integration of the implant. This is 
thought to prevent the uncoupling of load from the implant shoulder through load 
transfer. This strategy has focused on promoting bone growth over the implant by 
developing implant collars at the transaction site of the implant. The resultant "bony 
bridging" is also thought to act as a "purse string," sealing off the bone-implant 
interface, possibly preventing the migration of wear particles to the site causing 
osteolysis. However, it should be noted that the existence of these wear particles has not 
been proved empirically, unlike the polyethylene wear particles generated with 
traditional arthroplasty.  
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Figure 1.1 This figure shows a total hip arthroplasty. Lysis is seen around the acetabulum. 
Improving the cup bone osseointegration provides a biological bridge preventing the migration of 
lysis particles to the cup bone interface. 
 
Another method by which fixation of the implant could be improved is by using 
osteoblastic precursor cells such as bone marrow stromal cells (BMSC) in combination 
with HA-coated collars to further encourage greater bone growth and attachment into 
the implant collar. To augment this beneficial load transfer and reduce the aseptic 
loosening of massive implants using BMSC is the goal of this thesis. 
 
1.6 Stem cells 
 
1.6.1 Definition 
The term "stem cell" refers to an undifferentiated precursor cell that has "the capacity 
for unlimited or prolonged self-renewal, that can produce at least one type of highly 
differentiated descendant" (Watt and Hogan, 2000). These precursor cells can be 
induced to differentiate into another cell type, depending on the type of stem cell and 
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the cues given (Jaiswal et al., 1997). Between a fully multipotent stem cell and a 
terminally differentiated cell type, there are thought to exist a series of "committed 
progenitors" with a lower proliferative and differentiation potential. These can be 
referred to as "transit amplifying cells (Watt and Hogan, 2000). 
There are many sources of stem cells cited in the literature:  from the embryo, the adult 
bone marrow, umbilical cord blood, adipose tissue, as well as neuronal-derived cells 
(Bacou et al., 2004), (Lam et al., 2001); (Zvaifler et al., 2000); (Zandstra and Nagy, 
2001), all of which have varying abilities to differentiate down numerous cell lineages. 
As promising as these cell sources may be, most past and current research concerns the 
first three types of stem cell. It is becoming increasingly apparent however, that adult 
stem cells isolated from the bone marrow have potential regenerative applications (Le 
Blanc and Pittenger, 2005), such as the tissue engineering of bone (Arinzeh et al., 
2003), (Lee et al., 2005). 
Autologous, Allogeneic and Xenogenic Cells, and the Multipotency of stem cells: 
Definitions:  In cases where the stem cells from a patient are re-implanted into the same 
individual, the donor cells are referred to as being autologous. If donor cells are 
implanted into another individual of the same species, the cells are termed allogeneic, 
and of another species, xenogenic. A totipotent cell has the ability to differentiate into 
any type of cell and this is usually the property of embryonic stem cells. Pluripotent 
cells can differentiate into almost all cell types, but not all. A cell that can only 
differentiate into a limited number of cell types is termed multipotent (Zandstra and 
Nagy, 2001). 
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1.6.2 Bone Marrow Stromal Cells (BMSC) 
Bone marrow stromal cells (BMSC) are a population of plastic-adherent (capacity for 
adherence and growth on tissue culture plastic) cells derived from the bone marrow, that 
most often possess a fibroblastic morphology. BMSC, described as "fibroblastic 
precursor cells," were first described by Friedenstein, Chailakhjan and Lalykina in 1970 
(Friedenstein et al., 1970). A population of cells within this heterogeneous population 
(Aubin, 1998) are commonly referred to as "mesenchymal" stem cells, referring to their 
multi-potentency and/or ability to form mesodermal tissues such as bone (Haynesworth 
et al., 1992); (Jaiswal et al., 1997), cartilage (Johnstone et al., 1998) and adipose tissue 
(Ryden et al., 2003), and stroma (Majumdar et al., 2000). Friendenstein's seminal work 
investigated the properties of bone marrow stromal cells, in vitro, by observing their 
ability to mineralise after treatment with osteogenic supplements, and by their ability to 
form bony tissue in diffusion chambers invivo (Friedenstein et al., 1970); (Friedenstein 
et al., 1976); (Friedenstein et al., 1968). Bab, Ashton, et al. (1986) also investigated 
BMSC in diffusion chambers, and found that the tissues produced in these chambers 
originated from a small number of originally implanted cells with "stem cell-like" 
characteristics. Friedenstein proposed a hypotheses leading from his work that 
suggested a single stromal cell could give rise to multiple lines of cells (Friedenstein, 
1980). From their experimental data of CFU-F derived from the bone marrow, Owen, 
Cave, et al. (1987) produced a summary flow chart which indicated that stromal "stem 
cells" could differentiate into committed progenitors, which could then further 
differentiate into specific cell types such as fibroblasts, reticular cells, adipocytes, and 
osteoblasts. Dahir, et al. (2000) isolated  "precursor" cell lines from mouse bone 
marrow and was able to show by labelling cells with the enzyme 3-galactosidase (using 
a non-infections retrovirus containing the lacZ gene), that these cells not only had 
osteogenic characteristics in vitro, and were able to repopulate the bone marrow of host 
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mice, they maintained their osteogenic capability. 
However, there is some controversy as to whether or not BMSC are actually 'stem cells' 
as they are only multi-potent or have restricted differentiation potential, as opposed to 
embryonic stem cells (ESCs) which have the capacity to differentiate into almost any 
cell type (Heins et al., 2004); (Thomson et al., 1998). For this reason, the population of 
mononuclear, plastic-adherent, fibroblastic cells isolated from the bone marrow will be 
identified in this thesis as bone marrow stromal cells (BMSC), a term that refers to the 
cells origin and morphology. 
In culture, these cells are selected from the marrow based on the following 
characteristics: their mononuclear phenotype, their capacity for adherence and growth 
on tissue-culture plastic and their ability to form fibroblastic colony units (colony-
forming units-fibroblastic (CSFU- F). BMSC populations can also be enriched for 
"multipotent" cells or "stem cells," by selecting cells based on their surface marker 
expression pattern using fluorescence-activated cell sorter (FACS) or magnetic-
activated cell sorter (MACS) machines (Baksh et al., 2003); (Campagnoli et al., 2001); 
(Pittenger et al., 1999); (Watt and Hogan, 2000).  
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Listed below (Table 1.1) are a panel of cell surface markers used in BMSC 
identification, some of which are expected to be present and others absent. 
Surface markers present on BMSC CD29, CD44, CD54, CD71, CD90, 
CD120a, CD124, CD105 (Endoglyn), 
CD106 (VCAM-1), CD164 (Endolyn), 
SH2, SH3, SH4, Stro-1, P-ZR, (P zero 
protein) 
Surface markers absent on BMSC CD14, CD34, CD45, CD68, HLA-DR 
Table 1.1 Table illustrating cells surface markers present and absent on human BMSC (Baksh et 
al., 2003); (Campagnoli et al., 2001); (Pittenger et al., 1999); (Watt and Hogan, 2000). 
 
BMSC have great promise for tissue repair and regeneration, due to their ease of 
isolation, high proliferative capacity and ability to retain their multi-potent capacity, as 
well as their ability to differentiate into various mesenchymal tissues. In addition, the 
immuno-modulatory effects of BMSC should also be considered as this may permit the 
use of allogenic cells in patients. 
 
1.6.3 Previous characterisation of BMSC 
In current practice, the positive identification of BMSC as multipotent precursor cells 
can be achieved through two methods: differentiation of the cells down two or more 
lineages, and surface marker identification. Ideally, both methods should be utilised for 
complete characterization. 
Upon stimulation in culture with osteogenic reagents, BMSC change morphology and 
begin to express osteoblastic charactenstics temporally in the following order: cbfa-
l/runx2 and osterix transcription factors involved in osteoblast differentiation; alkaline 
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phosphatase which is expressed on the cell surface of osteoblasts; osteonectin, which 
regulates mineral- collagen interactions and calcium binding; osteopontin, involved in  
calcium deposition; and osteocalcin, which regulates the later stages of mineral 
deposition (Krishnan et al., 2003); (Pittenger et al., 1999). When differentiated towards 
the chondrogenic lineage, BMSC seem to upregulate the expression of collagen II (basic 
matrix molecule of articular cartilage), aggrecan, and sox-9, in addition to a 
chondrocytic phenotype (Lee et al., 2006); (Mackay et al., 1998). After treatment with 
adipogenic reagents, BMSC appear to accumulate lipid vesicles and are positive for the 
expression of genes such as lipoprotein lipase (LPL) and nuclear peroxisome 
proliferators-activated receptor gamma (PPAR72) (Pittenger et al., 1999).  
There has also been some evidence of neural and hepatocytic (Kang et al., 2005); (Lee 
et al., 2004) phenotypes being derived from BMSC, although this has also been 
disputed (Bertani et al., 2005); (Wang et al., 2003). Other groups have documented the 
differentiation of BMSC into cardiomyocytes and vascular cells (Nagaya et al., 2005). 
One group tracked cells and found that the implanted BMSC, in addition to releasing 
mitogenic, angiogenic, and anti- apoptotic factors in vitro, were positive for many 
cardiac markers once implanted into myocardia in vivo. 
As previously mentioned, human BMSC (hBMSC) can also be identified through the 
presence and absence of a series of cell surface markers, none of which are specific to 
BMSC (Baksh et al., 2003); (Campagnoli et al., 2001); (Pittenger et al., 1999). Recent 
research has identified the cell surface proteins CD164/endolyn and a specific isoform 
of P zero-related (PZR) protein as being markers of hBMSC (Watt and Hogan, 2000), 
albeit they are not entirely specific. There has been some preliminary work looking at 
the gene expression of BMSC that seems to also indicate that the patterns of gene 
expression of BMSC are unique (Djouad et al., 2005); however, this is not yet a 
commonly available tool for most laboratories. Whether or not all of these markers are 
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present or absent from the BMSC derived from other species is unknown.  
BMSC from other species have been isolated and either partially or fully characterised, 
such as from mice (Dennis and Charbord, 2002); (Phinney et al., 1999); rats (Lee et al., 
2005); (Okamoto et al., 2006), pigs (Bosch et al., 2006); (Vacanti et al., 2005), cats 
(Martin et al., 2002), dogs (Kadiyala et al., 1997); (Volk et al., 2005), goats (Kruyt et 
al., 2003), sheep (Kon et al., 2000); (Shang et al., 2001), cows (Troyer et al., 2003) and 
baboons (Bartholomew et al., 2001). 
Although Jiang, et al. (2002)were able to isolate a special population of cells from 
human, mouse and rat BMSC, called multipotent adult progenitor cells (MAPCs) that 
appeared to have pluripotency similar to ESCs, some of the FACS analysis for cells 
surface markers has been called into question (Verfaille, 2006), (Jiang, 2007) 
challenging the validity of the groups results. 
 
1.6.4 Proliferation rate of BMSC 
Human BMSC have been documented as having a high proliferation rate and can 
undergo as many as 38 population doublings without loss of their proliferative or 
osteogenic capacity (Bruder et al., 1997). This is almost twice the doubling capacity of 
other human diploid cell types, such as adult lung fibroblasts, which have a doubling 
capacity of 20 (Hayflick, 1965). With such prolonged expansion of BMSC in culture, 
there are accompanying concerns regarding cell ageing and mutation. Unlike 
undifferentiated embryonic stem cells [ESCs: (Heins et al., 2004)], BMSC do not 
express high levels of telomerase, the enzyme that legthens telomeres to prevent their 
shortening during cell division. As telomere shortening is directly related to cell ageing 
and senescence, there is a possibility that BMSC expanded in culture could lose their 
characteristics and ability to proliferate and differentiate once re-implanted in vivo 
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(Baxter et al., 2004). Another factor is an accumulation of mutations by the cells while 
in culture. It is well documented that not only immortalised tumour cell lines, but also 
BMSC cell lines could potentially mutate in artificial culture conditions (Devine et al., 
2001). This may result in errors in cell division or DNA repair, which lead to 
translocations (movement of one segment of a chromosome to another) as well as 
aneuploidy (Wang et al., 2005), which can be defined as having an abnormal number of 
chromosomes. In addition, BMSC-like cells have been isolated from giant cell bone 
tumours (Wulling et al., 2003). The possibility of accumulated cell damage and ageing 
should, therefore, be seriously considered when investigating BMSC and thorough 
testing should be in place to ensure that such potentially tumourogenic mutations have 
not occurred before re-implantation or infusion of cells. 
 
1.6.5 Immunogenetic properties of BMSC 
Current research suggests that BMSC have suppressive immunogenetic properties. The 
first evidence of an immunosuppressive effect of BMSC was their ability to promote 
recovery and engraftment of Haematopoietic Stem Cells (HSCs) in high-dose 
chemotherapy patients receiving HSC infusions (Koc et al., 2000). A number of in vitro 
experiments have assayed the effects of BMSC on mixed lymphoyte cultures (Le Blanc 
et al., 2003); (Tse et al., 2003). Le Blanc, et al. (2003) added different concentrations of 
both autologous and allogenic human BMSC to mixed lymphocyte cultures in an 
attempt to measure immunoreactivity of the BMSC. Not only did the group observe a 
cell-dosage effect of BMSC on the proliferation of lymphocytes and that BMSC were 
able to prevent the formation of activated T-lymphocytes, they also found that this 
effect was wholly independent of the major histocompatibility complex (MHC). 
Rasmusson, et al. (2003) obtained supporting results in a similar study.  
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Further work demonstrated that BMSC retained their immuno-suppressive properties 
after in vitro differentiation into osteogenic, chondrogenic, and adipogenic cells (Le 
Blanc et al., 2003). What is the mechanism of this immunomodulatory effect? BMSC 
express MHC I and lymphocyte function-associated antigen (LFA)-3 antigens as well as 
MHC II and ICAM-I antigens after stimulation with γ-interferon treatment (Tse et al., 
2003), but the observed effects are independent of the MHC. Evidence by Aggarwal and 
Pittenger (2005) showed that prostaglandin E2 (PGE2) plays a substantial role in 
mediating anti-inflammatory and immunomodulatory responses by showing a reversal 
of the immunosuppression after treatment with a known PGE inhibitor. It must be 
noted, however, that an earlier experiment by Tse et al. (2003) found that inhibiting 
PGE, had no such effect. The mechanism of BMSC-modulated immunosuppression has 
not been conclusively studied as yet, however, this property may explain the acceptance 
and effectiveness of allogeneic cells in a few bone tissue engineering models (Tsuchida 
et al., 2003) (Arinzeh et al., 2003); (De Kok et al., 2003) . In these models, allogeneic 
BMSC have performed as well as autologous BMSC in regenerating defects with new 
bone. 
 
1.6.6 Haematopoietic Stem Cells (HSCs) 
HSCs are precursors of the haematopoietic lineage, which are predominantly localised 
to the bone marrow in their undifferentiated state, and most often derived from this 
source.  Till and McCulloch (1980) first documented the multipotency of these bone 
marrow-derived cells after an injection of HSCs into lethally irradiated mice resulted in 
the formation of donor-derived haematopoietic colonies of various lineages. In 
comparison to BMSC, HSCs are well documented in terms of their differentiation 
pathways and mechanisms, localisation and attachment in the marrow, and the clinical 
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results from transplanting these cells into human patients. Donor HSC infusions have 
proven to be clinically effective in the treatment of neutropenia (Reddy, 2005). This 
often involves a selection of cells expressing the cell surface marker CD34 using 
fluorescence-activated cell sorting (FACS) from a plasma-depleted blood donation, 
followed by infusion of these cells into the patient. Clinically HSCs are often mobilised 
using granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage-
colony stimulating factor (GM-CSF). The mobilisation of these cells is mediated via the 
binding of HSCs to the bone marrow stroma. Upon stimulation, the HSC cell surface 
receptor CXCR4 dissociates from the cytokine stromal-cell derived factor-1 (SDF-1), a 
factor expressed by BMSC and other cells of the stromal lineage. A second mechanism 
involves the release of the HSC adhesion molecule VLA-4 from vascular cell adhesion 
molecule-1 (VCAM-1), which is expressed on the surface of BMSC. In both cases, 
there is liberation of proteases such as elastase, cathepsin G and matrix metalloproteases 
(MMPs) such as MMP-9, which result in the degradation of these molecules involved in 
adhesion as well as a subsequent remodelling of the ECM microenviromnent to promote 
release of cells from the marrow (Lapidot and Petit, 2002). 
 
1.6.7 Embryonic Stem Cells (ESCs) 
Embryonic stem cells (ESCs) are isolated from the inner cell mass of pre-implantation. 
ESCs were first isolated from mice by Martin Evans in 1981 (Evans and Kaufman, 
1981). Human embryonic stem cells were first successfully isolated and cultured into 
cell lines in 1998 by (Thomson et al., 1998). ESCs are pluripotent, as they can 
differentiate into almost any cell type except extra-embryonic cell types such as the yolk 
sac visceral endoderm, parietal endoderm, and placental trophoblast (Zandstra and 
Nagy, 2001).  
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The advantage of using ESCs is their ability to differentiate into any tissue derived from 
the three embyonic lineages (ectoderm, mesodenn, and endoderm) in two or three-
dimension culture. Also ESCs hold great promise in the pharmaceutical industry for 
drug discovery and toxicity testing. At present, there are insufficient sources of 
specialised human cell types such as those derived from the liver or heart (hepatocytes 
or cardiomyocytes). By differentiating the highly proliferative, pluripotent ESCs into 
these cell types, new cells would be available for in vitro testing. In fact, as discussed by 
(Ameen et al., 2008) these cells could even be used to derive cells that could activate 
and mobilise endogenous cells to organs or tissues in need of repair or improved 
function. 
The potential disadvantages of using ESCs are numerous, and include the difficulties 
and expense associated with ESCs (Le Blanc and Pittenger, 2005). It is impossible to 
use autologous ESCs, which are derived from embryos, as there are immunoreactivity 
issues to be considered in transplanting human leukocyte antigen (HLA)-mismatched 
cells into patients (Heng et al., 2005). When using BMSC, it is possible to use 
autologous cells from the patient, expand those cells, and re-implant them without any 
donor-related risks. Another disadvantage is the difficulty in culturing ESCs. Although 
ESCs can be grown and expanded in vitro, if they not maintained under strict control, 
the cells spontaneously differentiate into different cells, some of which may not be the 
desired type (Heng et al., 2005). For example, a study investigating ESCs administered 
in vivo in immune-compromised mice Tzukerman et al. (2003) showed that ESCs can 
give rise to teratomas and are tumourogenic. However, if ESCs were pre-differentiated 
into specific cell types before implantation, the probability of terartomic activity could 
decrease significantly (Ameen et al., 2008). These factors have limited the potential of 
ESCs for clinical application. The third, and perhaps most controversial consideration in 
using ESCs, is the ethical and legal dilemma posed by their potential use clinically. An 
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important source of human ESCs is embryos created through in vitro fertilisation 
procedures. The moral idea that embryos have the potential to become human beings 
and, therefore, should not be dissected for use in research, and/or clinical practice, has 
made the use of human embryos both difficult practically and ethically controversial 
(Shenfield, 2005); (Young, 2000). When mesenchymal tissues are regenerated in tissue 
engineering, adult stem cells such as BMSC have been preferred as they are readily 
available, can be isolated from the patient who could be receiving therapy (as 
autologous cells), and have the potential to differentiate into the tissue of interest. 
 
1.7 Tissue engineering 
 
1.7.1 Introduction 
Organ and tissue transplants have been used for some time in clinical practice in many 
areas of medicine with varying levels of success. Supply and demand as well as 
immunocompatibility and disease transmission are big issues in transplantation that 
often render them impossible or risky. Immunosuppressive drugs taken to accept these 
organ transplants can lead to tumour formation (Vacanti et al., 2000). By creating 
tissues using the basic components of cells, scaffolds, and bioactive factors, tissue 
engineering attempts to replace, re-construct, or repair tissues. There are two main 
approaches in this field, which are in vitro (or ex vivo) and in vivo tissue engineering. In 
vitro tissue engineering strives to create tissue outside the body. This may require the 
use of tissue culture techniques, in addition to bioreactors, bioactive factors, and 
specially designed scaffolds and biomaterials. 
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1.7.2 Scaffolds 
One of the important components of tissues in the body, apart from the cells themselves, 
is the extracellular matrix (ECM) that they lay down. ECM serves a variety of 
functions, from general structural support of the tissue, to involvement in cell alignment 
and communication (Petreaca et al., 2007). This matrix is predominantly collagen-
based, although other molecules such as hyaluronic acid, glycoproteins, elastins, 
fibronectin, vitronectin and laminin are also important components (Pearson et al., 
2002). Embedded within the fibrils of these matrix materials, various growth factors can 
be found as well as water molecules and enzymes such as elastases or metalloproteases 
(Petreaca et al., 2007). In tissue engineering, scaffolds attempt to simulate a native 
tissue environment with an artificial extracellular matrix. Ideally, the material should 
also be biodegradable (Pachence et al., 2000). Thus, popular scaffolds used include 
collagen I, alginate, poly-lactic acid (PLA), poly-glycolic acid (PGA), plasma, as well 
as fibronectin and fibrin (Andree et al., 2001); (Gurevich et al., 2002); (King et al., 
2006); (Kumar and Albala, 2001); (Pachence et al., 2000); (Ting et al., 1998); (Ye et al., 
2000). 
In bone tissue engineering, a mechanically supportive, osteoconductive, ceramic 
scaffold such as natural coral exoskeleton, synthetic hydroxyapatite, beta-calcium 
triphosphate or Bioglass may be used (Chan et al., 2002); (Oonishi et al., 1997), often in 
combination with one of the above mentioned matrix materials. These scaffolds have 
inherent osteoinductive (Ripamonti, 1996); (Yuan et al., 1998) and/or osteoconductive 
properties (Geesink and Hoefnagels, 1995). Newly developed biomaterials include silk-
based scaffolds (Meinel et al., 2005) and chitin-based scaffolds (Di Martino et al., 
2005), which appear to be osteoconductive in vivo. BMSC are generally combined with 
one or a combination of these scaffolds with or without growth factors, for bone tissue 
engineering (Bruder et al., 2000). 
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Porosity and pore sizes have been investigated for their effects on bone regeneration 
with scaffolds, with or without cells being added. Various works report that, overall, the 
minimum pore size of a structure should be greater than 300 µm, to allow for cell 
migration into the, pores, nutrient migration, as well as to allow the invasion of 
capillaries into the site; vasculogenesis being an important first step towards 
osteogenesis (Kuboki et al., 2001); (Tsuruga et al., 1997); (Gotz et al., 2004). While 
smaller pores can contribute to hypoxic conditions and the aggregation of cells, 
resulting in osteochondral ossification, larger pores allow for direct osteogenesis. 
Although higher scaffold porosity encourages better bone in-growth, increasing porosity 
often decreases the mechanical strength of a scaffold, to the point where it is no longer 
withstanding the loads seen in orthopaedic applications (Karageorgiou and Kaplan, 
2005). 
 
1.7.3 Fibrin Glue 
Fibrin is a naturally occurring matrix which has an important role in the final steps of 
the coagulation cascade in wound healing, and has been used previously as a tissue 
engineering scaffold (Grant et al., 2002); (Lee et al., 2005). In the body, fibrin is formed 
by the enzymatic cleavage of the fibrin zymogen fibrinogen by the serine protease 
thrombin. Fibrin then undergoes a polymerisation reaction with other fibrin molecules, 
as well as cross-linking (facilitated through either Factor XIII or endogenous trans-
glutaminases) to itself and surrounding tissue, which lends it both haemostatic and 
adhesive properties (Marx and Mou, 2002). Fibrinogen fragments as well as fibrin 
degradation products are thought to promote the migration of cells such as fibroblasts 
(Abiraman et al., 2002) and vascular smooth muscle cells to the healing site (Kodama et 
al., 2002). Fibrinogen-fibroblast interactions have not been thoroughly investigated 
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(Gailit et al., 1997). Fibroblasts are thought to interact with fibrin by the interaction of 
fibrinogen molecules with the integrins œyßi, œyfis, œiibßs (Jeffrey A et al., 2007). 
Integrins are a large family of cell surface receptors involved in adhesion by binding to 
ligands found expressed in the ECM and by other cells (Gailit et al., 1997). Although 
there is evidence for direct fibroblast-fibrinogen interactions in cell adhesion, evidence 
shows that indirect interactions with fibronectin are required for cell spreading and 
migration into fibrin via the crucial integrin binding to the sequence RGDS (Gailit et al., 
1997); (Knox et al., 1986); (Pierschbacher and Ruoslahti, 1984). 
Cells naturally express urokinase plasminogen activator and tissue plasminogen 
activator, serine proteases that activate the fibrin-degradation enzyme plasmin (Neuss et 
al., 2004), and this process, in addition to the action of macrophages and multi-
nucleated foreign body cells, naturally degrades fibrin over time. 
Fibrin glue has been used for many years as a surgical haemostatic agent (Davidson et 
al., 2000); (Spotnitz et al., 1987), as well as other surgical uses, for example, preventing 
air leaks after pulmonary resection (Belboul et al., 2004). Fibrin glue can also be 
sprayed. Commercially prepared fibrin glue, such as Tissucol® and Tisseel® fibrin 
sealant, have two main components: human fibrinogen reconstituted in a bovine 
aprotinin solution, and a human thrombin-calcium chloride solution. The availability of 
fibrin, in addition to its simple application system, makes it easy to obtain and use. 
Combinations of fibrin and non-resorbable HA have been used throughout Europe for 
over a decade, in the reconstruction of maxillofacial and dental defects (Bonucci et al., 
1997). The fibrin phase has proved effective in moulding ceramic scaffolds and holding 
the granules/powder in place as natural mineral deposition occurs. 
At present, fibrin is a promising scaffold for cells for skin regeneration, and when 
combined with keratinocytes, can be sprayed onto wound sites (Grant et al., 2002). 
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Fibrin has been shown to increase the level of the angiogenic factor VEGF, which could 
enhance the healing effect of fibrin scaffolds in skin tissue engineering (Hojo et al., 
2003). 
The osteoconductive properties of fibrin glue have been reported (Abiraman et al., 
2002); (Bosch et al., 1980); (Kania et al., 1998); (Yamada et al., 2003) and disputed 
(Greco et al., 1988); (Lucht et al., 1986); (Schwarz et al., 1993). An experiment by 
Abiraman, et al. (2002) showed that fibrin glue had osteoconductive properties at an 
ectopic site; however, this was only observed when fibrin was combined with 
hydroxyapatite or bioglass. Similar work in a rat femoral defect model indicated a role 
for fibrin glue in osteogenesis when implanted in an orthotopic site. In another study by 
Schwarz, et al. (1993) fibrin glue did not promote osteoinduction at both ectopic and 
orthotopic locations in rats. Thus, no study has shown fibrin alone to possess 
osteoinductive properties. 
Fibrin may not induce differentiation of osteoblastic precursors into osteoblasts, but 
may promote neo-vascularisation at the surgical site to promote faster healing and bone 
formation and organisation (Kania et al., 1998). In the osteoconductive experiments 
described above, control biomaterials such as bioglass and hydroxyapatite granules did 
not show reduced bone formation and bone ingrowth to materials when compared to 
those treated with fibrin, but also lacked neo-angiogenesis (Kania et al., 1998). A study 
by Abiraman, et al. (2002) demonstrated that the ectopic implants coated in fibrin glue 
had noticeable neo-vascularisation and evidence of intramembranous ossification when 
compared to controls, which were encapsulated in a thick fibrous layer. 
Fibrin's biocompatibility, commercial availability, in addition to its proven effectiveness 
in bone defects, makes it an ideal cell delivery vehicle for cells such as BMSC in in vivo 
tissue engineering adaptations. 
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1.7.4 The use of BMSC in the tissue engineering of bone 
The first evidence indicating the osteoinductive nature of bone marrow cells was the 
ability of fresh bone marrow to augment bone formation in orthopaedic surgery (Boyne 
and Yeager, 1969); (Morris, 1969). Following the seminal work of Friedenstein, et al. 
(1968) into the role of BMSC specifically in bone formation, they have become a major 
component of bone tissue engineering strategies. One benefit of using BMSC as 
opposed to bone marrow is the lack of erythrocytes, which may increase potassium to 
cytotoxic levels (Street et al., 2000). In vitro testing has frequently been used as a pre-
indicator of osteogenic capabilities of osteoprogenitor cells and cell-scaffold costructs 
in vivo (Jaiswal et al., 1997), (Rust, 2004). BMSC have been shown to increase bone 
growth in vivo in small and large animal models at both orthotopic and ectopic 
locations (Bruder et al., 2000); (Haynesworth et al., 1992), (Kalia et al., 2006); (Korda 
et al., 2006); (Kruyt et al., 2003). Some of the first experiments investigating the 
potential of BMSC in in vivo, loaded cubes of calcium phosphate ceramics with or 
without BMSC, which were implanted subcutaneously in synergenic or immuno-
compromised rodents (Haynesworth et al., 1992). These studies found significantly 
increased bone growth into the cubes loaded with BMSC when compared to the 
scaffolds alone. Further work by this group showed that this observation was applicable 
to cells from many mammalian species, such as goats, sheep, dogs, rats, and humans. 
Additionally, it was found that diluting the number BMSC up to 50% with fibroblasts 
did not effect bone formation in vivo (Bruder et al., 2000). In addition to smaller 
animals such as mice, rats, and rabbits, larger animals such as dogs, sheep, and goats, 
are often used for the in vivo testing of bone tissue engineering strategies. The results of 
in vivo investigations on the mechanical loading of the hind limbs of large animals 
indicate similar loading levels to those experienced by humans (Bergmann et al., 1984); 
(Buma et al., 2004); (Martini et al., 2001), suggesting that large animals may be a 
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suitable model for the testing of tissue engineering models with BMSC. A study 
investigating ectopic bone growth in a caprine model showed a significant effect of 
BMSC loaded seven days pre-operatively or per-operatively onto porous ceramic cubes, 
suspended in autologous plasma, and implanted into the bilateral paraspinal muscles of 
goats (Kruyt et al., 2004). This biphasic calcium phosphate (BCP) scaffold has 
previously been shown to be osteoinductive, in that it promotes bone growth in an 
ectopic site, without the aid of osteoinductive growth factors or osteoprogenitor cells 
(Yuan et al., 2002). In the 2004 ectopic study by Kruyt, et al., a comparison was made 
between cryopreserved and fresh cells to see if cells could be obtained in advance of 
surgery and preserved for future use. These groups were also compared to control, 
untreated scaffolds as well as devitalized scaffolds. These are scaffolds which have cells 
grown onto them for seven days, after which the construct is devitalised to remove the 
cells, leaving behind an extracellular matrix coating. In this study, it was found that 
these ceramic blocks had significantly more bone growth when seeded pre-operatively 
or per-operatively with BMSC compared to the scaffold only or a devitalised cell 
matrix/scaffold combination. 
 
Kon, et al. (2000) preceded their orthotopic, large animal work with a small animal 
study demonstrating the osteoinductive effects of ovine BMSC when loaded into fibrin-
coated HA blocks, and implanted subcutaneously in nude mice. Interestingly, it has 
been suggested that an ectopic intramuscular site, which is extremely vascular, could be 
an effective in vivo bioreactor for bone tissue (Stevens et al., 2005); (Warnke et al., 
2006).  
 
Bone tissue engineering can also be applied to cases where bone has been resected to 
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treat tumours such as high-grade osteosarcomas, Ewing's sarcoma, or malignant fibrous 
histiocytoma (Kenan, 1991). The patients are given pre-operative and post-operative 
chemotherapy to prevent the spread of the tumour and the possibility of metastases. One 
study demonstrated an improvement in five-year survival of stage IIB osteosarcoma 
patients from 32 without chemotherapy to 57 with this treatment (Eckardt et al., 1991a). 
Lee, et al. (2005) showed a negative effect of a neoadjuvant chemotherapy regime on 
BMSC proliferation on osteogenesis in vitro and new bone formation in a rat osteotomy 
model, by using a combination of doxorubicin and cisplatin. However, he was also able 
to demonstrate in a rat femoral defect model with external fixation that the application 
of fibrin glue and BMSC to the defect site resulted in similar amounts of bone 
formation, whether or not the rats had been given chemotherapy. Therefore, both these 
studies indicate a role for BMSC in bone regeneration after chemotherapy, as well as 
the effectiveness of BMSC in combination with fibrin glue for augmenting new bone 
formation at an orthotopic site.  
 
In 1998, Bruder, et al. demonstrated the effectiveness of autologous BMSC in the 
healing of canine segmental bone defects, when the cells were loaded onto a 
fibronectin-coated, ß-TCP cylindrical construct. The femoral implants were supported 
by a lengthening plate and left in situ for 16 weeks. In this case, the BMSC resulted in a 
noticeable bony callus around the implant, as well as significantly more bone formation 
than the controls (untreated with fibronectin and cell-free). Untreated defects (with no 
implant or treatment) resulted in non-unions after sixteen weeks, and those ceramic 
implants that were not cell-loaded began to show signs of cracking at twelve weeks, in 
contrast to the cell-loaded implants. This same group demonstrated similar results after 
16 weeks in the same canine defect model, but this time substituting allogeneic BMSC 
that were dog leukocyte antigen (DLA, analogous to HLA) mismatched as opposed to 
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autologous cells (Arinzeh et al., 2003). Petite, et al. (2000) attempted critical-sized 
defect bone regeneration with the aim of preventing non-union. As an alternative to 
autograft, the group created a BMSC-coral "biohybrid," and compared bone formation 
and union of the scaffold to host bone in an ovine model. The group first established the 
minimum length for non-union in sheep by creating a series of metatarsal defects and 
observing their ability to achieve union, that is, ability to heal and form new bone to 
bridge the gap rather than become scarred (Petite et al., 2000). They then created a 
"biohybrid" to fit the critical-size defect and tested BMSC-loaded coral constructs and 
fresh bone marrow-loaded constructs to cell-free scaffold controls and untreated defects. 
They found that while the untreated defects did not heal after 16 weeks, cell-free 
scaffolds achieved some bone growth, although they did not integrate into the host 
bone. Those constructs containing fresh bone marrow were filled with fibrous tissue 
more akin to scar tissue than bone formation, whereas BMSC-loaded constructs 
demonstrated mostly new bone formation and union with the host bone (Petite et al., 
2000). 
 
In another large animal model, a BMSC-loaded construct was implanted into critically 
sized defects of sheep and BMSC were loaded into HA cylinders by coating them with 
fibrin and absorbing a cell solution into the fibrin-ceramic scaffold. This cell-loaded 
group had noticeably more bone growth into the construct, as well as greater callus 
formation around the implant bridging to the host bone (Kon et al., 2000). However, it 
must be noted that the group size was too small for meaningful statistical analysis.  
Similarly, for other types of tissue engineering of mesenchymal tissues such as articular 
cartilage and craniofacial tissue (Frosch et al., 2006); (Shang et al., 2001) ceramic or 
metal implants have been used as a scaffold for BMSC, and tested in large animal 
models. In these cases it has been shown that BMSC can be used to restore other tissues 
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that provide important functional and or aesthetic roles. 
 
1.8 Growth factors: Cytokines to target bone formation and 
revasularisation 
 
In an effort to stimulate natural molecular mechanisms that trigger bone formation, one 
can implant growth factors at a site where bone regeneration or formation is required, or 
incorporate them into a scaffold in the presence or absence of osteoprogenitor or 
osteoinductive cells. These factors can be used to target the temporal mechanism of 
bone growth. In this case bone morphogenetic proteins such as BMP-2, BMP-4, BMP-7 
or BMP-9 can be used to promote fracture healing or healing of critical sized defects 
(Lin et al., 2005); (Mistry and Mikos, 2005). Genes that also have been demonstrated to 
promote bone formation include sonic hedgehog (Edwards et al., 2005) and Runx2 
(Byers et al., 2006). Vascularisation can be promoted by using growth factors such as 
VEGF, whether by direct protein or gene (DNA) injection into a site of bone repair 
(Geiger et al., 2005); (Huang et al., 2005). There are, however, some disadvantages to 
using growth factors, such as their great expense, making regular use exorbitant. For 
example, a study by (Dimitriou et al., 2005) found that the average cost of treating a 
fracture non-union with BMP-7 was approximately £7,338. In an American study by the 
Washington State Department of Labour and Industries (2003), treating a tibial non-
union with BMP-2 cost approximately $12,468 (about £6,764), which was about the 
same cost as treatment with autograft. Also, the effectiveness of growth factors is not 
completely predictable, and in some cases is comparative to the use of autograft 
(Friedlaender et al., 2001); (Maniscalco et al., 2002). Autograft in this scenario refers to 
bone graft harvested from another site on the patient, such as the iliac crest (Burkus et 
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al., 2003). Similarly, osteoprogenitor cells or other cell types used for tissue engineering 
purposes can be genetically modified to express these growth factors. Use of a 
temporary vector, such as replication-incompetent adenovirus, which will insert its 
DNA into host cells and express the protein for a limited period of time, has its 
advantages (Lieberman et al., 1999); (Tsuchida et al., 2003). These advantages include 
the targeted temporal expression of the genes of interest, as well as preventing over-
expression of the gene, and not using a virus that inserts into nuclear DNA prevents the 
risk of adverse immune reactions or the formation of a recombination-competent virus. 
In some cases, the adenoviral vector has been injected directly into a site of repair 
(Kang et al., 2004). 
However, long-term expression of growth factors by cells can be achieved by using 
retroviral vectors. Replication incompetent retroviruses have been used to insert genes 
into the host genome of cells being implanted for use in bone tissue engineering 
(Breitbart et al., 1999); (Mason et al., 2000). 
 
1.9 Goals 
 
The main hypothesis of this thesis is that viable BMSC can be applied to implants using 
a fibrin glue-spray system, and increase bone formation adjacent to the implants and 
improve bone-implant contact. 
This work aimed to improve fixation of orthopaedic implants to host bone in an attempt 
to reduce rates of aseptic loosening, and can be divided into four main aims: 
1) To demonstrate the ability of BMSC to improve implant fixation in a large animal 
using practical scenarios such as total hip replacement, massive endoprosthetic 
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replacement and bone defect around pins. 
2) To study the effect of varying cell dosages of BMSC in their ability to produce new 
bone and improve bone implant contact. 
3) To study the effect of differentiating the BMSC along the osteogenic pathway in their 
ability to produce new bone and improve bone implant contact. 
4) To study the effect of using semi-permeable barriers around BMSC sprayed on 
implants to prevent cell migration.  
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of BMSC Suspended in Fibrin Glue onto the 
Surface of Implants 
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2.1 Introduction 
 
In the first part of this chapter, I have discussed the process of isolation, expansion and 
characterisation of BMSC from iliac crest bone marrow aspirates. In the second part of 
this chapter, I have discussed the spraying technique we have developed to coat implant 
surfaces with BMSC. The techniques described here are modified from the earlier work 
undertaken in our research centre (Rust, 2004, Kalia, 2007). In my subsequent 
experiments described in Chapters 3, 4 and 5 in this thesis, I have followed the 
methodology described here for the isolation and expansion of cells and for spraying the 
BMSC on the surface of implants intra-operatively. 
 
2.2 Isolation, Culture expansion and Characterization of BMSC  
 
2.2.1 Aspiration of BMSC 
 
2.2.2 Animal model 
English mule ewes were used to test the massive endoprosthesis model and tibial pin 
model. Sannan goats were used for the total hip replacement model. These animals were 
skeletally mature (two to five years in age), and weighed between 65-90 kg. All 
procedures were carried out according to the Home Office Animals Scientific 
Procedures Act of 1986. I held a personal license for animal handling during the period 
for which the experiments were undertaken. The technique of bone marrow aspiration is 
described below. The process of preparing the animals for surgery explained here was 
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followed in all operative procedures described in this thesis. 
 
2.2.3 Anaesthesia and Pre-Operative Preparation 
All animals were brought into the preparation room from their pens on the day of 
surgery and their vital measurements (blood pressure, pulse, respiratory rate and 
temperature) were recorded. Per-anaesthetic medication in the form of an intramuscular 
(IM) injection of Xyalzine (0.1 mg/kg, Rompun, Bayer Health Care, Newbury, 
Berkshire, UK), was administered approximately 30 minutes prior to induction of 
anaesthesia. Anaesthesia was induced using a combination of intravenously 
administered Ketamine (2 mg/kg, Ketaset, Fort Dodge Animal Health Ltd, 
Southampton, UK) and Midazolam (2.5 mg, Hypnovel, Roche Products Ltd., Welwyn 
Garden City, Hertfordshire, UK) intravenously (IV) injected into the external jugular 
vein. This was followed by a rapid sequence endotracheal intubation and attachment to 
an anaesthetic machine. A mixture of 2% halothane (Merial Animal Health Ltd., 
Harlow, Essex, UK) and oxygen, delivered at an optimum titrated volume was used to 
maintain the anaesthesia throughout the procedure. Continuous monitoring of the 
respiratory and cardiovascular parameters was undertaken from the time of 
administering the pre-medication, until the animals completely recovered and were 
transferred back to their pens. A stomach tube was routinely inserted to allow 
continuous drainage during the procedure and prevent the risk of aspiration from the 
reflux of gastrointestinal contents.  
 
2.2.4 Procedure for Bone Marrow Aspiration 
Prior to transfer to the surgical procedure room, an approximate area of 10 cm
2 
of the 
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skin overlying the iliac crest was prepared for the procedure by shaving and then 
scrubbing with an antiseptic solution Pevidine, a Povidone-iodine scrub antiseptic 
solution (C-Vet, Bury St. Edmunds, UK). A fenestrated drape was used to protect the 
prepared surgical site from contamination until the scrubbed surgeon undertook further 
skin preparation.  
The surgical site was scrubbed using a 0.5w/v chlorohexidine gluconate solution in 
spirit (Adams Healthcare, Leeds, UK) as a sterilizing agent and the animal was draped 
with sterile towels, exposing only the desired site. 
The bony prominence of the iliac crest was then palpated and a 1cm incision was 
positioned on top of the bone. A surgical artery clip was used to blunt-dissect the soft 
tissues between the skin and the bone. The intramedullary cavity of the iliac crest was 
penetrated with a commercially available Jamshidi biopsy needle (R56780, Rocket 
Medical, Washington, UK) using constant pressure and a screwing motion. Routinely, 8 
mL of bone marrow was aspirated, in two separate 4 mL aliquots taken from a deeper or 
shallower site (Rust, 2004), (Kalia, 2007). The aspirate was collected in syringes pre 
loaded with 0.5 mL heparin (1000 units/mL) (Monoparin, CP Pharmaceuticals, 
Bamstable, UK) to prevent coagulation of the samples.  
Post-operatively, all animals were given 0.6 mg Buprenorphine as an analgesic 
(Vetergesic, Alstoe Animal Health, Melton, Mowbray, UK), as well as a long-acting 
antibiotic (15 mg/kg Amoxillicin, Betamox LA, Norbrook Laboratories (GB) Ltd., 
Great Corby, Carlisle, UK). 
 
2.2.5 BMSC Isolation and Culture Expansion 
The components of bone marrow were separated using a sucrose gradient and density 
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centrifugation. The procedures were undertaken in a designated laboratory under a 
lamellar flow hood using universal safety precautions. 
Four mL of bone marrow aspirate was carefully layered on top of 3 mL of Ficoll-
Paque™ PLUS sucrose gradient (17-1440-02, Amersham Biosciences, Chalfont St. 
Giles, UK). The layered samples were centrifuged at a temperature of 4°C for 30 
minutes at a velocity of 1500 rotations per minute (rpm). The centrifuge segregated two 
layers. The lower layer had a distinct upper ‘buffy’ portion separating it from the upper 
layer. This ‘buffy layer’ contains the mononuclear cells of the bone marrow (Ficoll® 
users’ guide). The buffy layer was carefully transferred into a universal container and 
washed in a solution of 10 mL of DMEM media (DMEM+, or control media), 
supplemented with 10% fetal calf serum (FCS, First Link, UK) and l00 units/mL 
penicillin/streptomycin (P/S, 0082, Invitrogen, Paisley, UK) to form a cell suspension. 
The cell suspension was then centrifuged at room temperature for 5 minutes at a 
velocity of 2000 rpm. The supernatant was discarded and the remaining pellet 
resuspended in 1 mL DMEM+ using a 21 gauge needle and 1 mL syringe before being 
transferred to a T25 polystyrene cell culture flask (Coming, Coming, NY, USA) with 4 
mL of media. This flask has a surface area of 25 cm
2 
for cell expansion, and a treated 
(using oxidizing chemicals) surface for cell adhesion (Ramsey et al., 1984), (Amstein 
and Hartman, 1975). 
Flasks were stored in a humidified incubator at 37°C, with 5% CO2. Over 7-14 days, the 
cells expanded over the surface of the flask and colony-forming units (CFU-Fs) 
appeared. Once 70% of the culture surface was covered with cells, (70% confluent), the 
following steps were undertaken to expand the cells further (known as ‘passaging’). 
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2.2.6 ‘Passaging’ of BMSC and the ‘Live-Dead’ Assay 
The culture media (DMEM+) was pipetted out and the cells were washed with cold 
phosphate buffered saline (PBS). After the excess PBS was pipetted out, a 0.5% trypsin 
solution [0.5% trypsin-5.3 mM EDTA-4Na solution (15400-054, Invitrogen, Paisley, 
UK)], prepared by diluting a 10x stock solution with PBS was added to the cells in the 
culture flask. The culture flask was incubated for 5 minutes at 37°C. The trypsin lifts 
the cells off the culture surface. After 5 minutes, a 1:1 volume of DMEM+ is added to 
the culture flask to neutralize the effect of trypsin. 
In order to determine cell viability, a 0.4% Trypan Blue solution (Sigma-Aldrich, 
Dorset, UK) was then used in a 1:1 ratio with a small quantity of the cell suspension. A 
haemocytometer was used to quantify the concentration of cells under a phase-contrast 
light microscope. Trypan Blue is a dye with two azo chromophores. The chromaphore is 
negatively charged, and thus, only reacts with cells when the membrane is damaged. 
Therefore, it is assumed that the (blue) stained cells are dead and the unstained (clear) 
cells are alive (Biosource AlamarBlue™ manual). The cell suspension was then 
centrifuged for 5 minutes at 2000 rpm at room temperature to obtain a cell pellet. The 
supernatant was discarded and the cell pellet was then resuspended in 1 mL of DMEM+ 
(control media) using a 21 gauge needle and syringe. Approximately 3,000 - 4,000 cells 
were seeded per cm
2
 of cell culture area and cells cultured in 0.1333 mL of DMEM+ 
(control media) per cm
2
 of surface area. DMEM+ (control media) media was changed 
every 3-5 days. This technique was used to expand cells when they reached 70-80% 
confluence on the cell culture flasks, until passage 3-4 at which time they were used in 
in vitro and in vivo experiments. 
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2.2.7 Differentiation of Bone Marrow Stromal Cells 
 
2.2.8 Osteogenic Differentiation 
Osteogenic Media (Rust, 2004), (Kalia, 2007). 
Dulbecco's Modified Eagle's Medium (DMEM) (4500 mg/L glucose, D6429, Sigma-
Aldrich, Dorset, UK) 
10%  Fetal calf serum (FCS; First Link, UK) 
1%  Penicillin/streptomycin (P/S; 0082, Invitrogen, Paisley, UK) 
l.0 x 10
-7
 M  Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK) 
5.0 x 10
-4
 M  Ascorbic Acid (255564, Sigma-Aldrich, Dorset UK) 
1.0 x 10
-2
 M  β-glycerophosphate (G9891, Sigma-Aldrich, Dorset, UK) 
BMSC were isolated, expanded, and trypsinised as described above. For histochemical 
staining (Von Kossa staining), 6 x 10
4
 cells were plated out onto Thermanox® 
coverslips (Nalge Nunc intemational. Rochester, NY, USA), which had been placed at 
the bottom of the wells of 12-well plates (Coming, NY, USA). 1 mL of supplemented 
osteogenic media was added to each well. Cells were grown in a standard humidified 
incubator, and media was changed every 3-5 days. Cell morphology was observed every 
5-7 days, up to 28 days after the initiation of culture. 
For the alkaline phosphatase (ALP) assay, 6.0 x 10
4
 cells were plated into 6-well plates 
(Nunc. NJ, USA) and grown for 7, 14, 21 and 28 days. For each cell line, there were 
two groups: cells grown in standard supplemented media, and cells grown in osteogenic 
media. Each group was repeated in triplicate for each time point. 
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2.2.9 Adiopogenic differentiation 
Adipogenic Media [from (Kalia, 2007), (Rust, 2004)] 
 
Dulbecco's Modified Eagle's Medium (DMEM) (4500 mg/L glucose, D6429  
Sigma-Aldrich, Dorset, UK)  
10%  Fetal calf serum (FCS; First Link, UK) 
1%  Penicillin/streptomycin (P/S; 0082, Invitrogen, Paisley, UK) 
l.0 x 10
-6
 M  Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK) 
200µM Indomethacin (I7378, Sigma-Aldrich, Dorset, UK) 
500µM 1 -methyl-3-isobutylxanthine (15879, Sigma-Aldrich, Dorset, UK) 
10µg/mL Insulin (I0516, Sigma-Aldrich, Dorset, UK) 
 
For adipogenesis, 1x10
5
 cells were cultured per well in 12-well plates, on Thermanox 
coverslips. Cells were cultured in adipogenic media for 21 days, with media being 
changed every 3-5 days. After 21 days, cells were fixed in 10 % neutral buffered saline 
(NBS). Adipogenesis was confirmed using Oil red ‘O’ staining.  
 
2.2.10 Chondrogenic differentiation: 
Chondrogenic Media [modified from (Rust, 2004), (Kalia, 2007)] 
High-glucose DMEM (4500 mg/L, D6429, Sigma-Aldrich, Dorset, 
UK) 
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1.0%  P/S (0082, Invitrogen, Paisley, UK)) 
1.0 x 10 
-7 
Dexamethasone, water-soluble (D2915, Sigma-Aldrich, Dorset, UK) 
50 ng/mL Ascorbic Acid (A4544, Sigma-Aldrich, Dorset, UK) 
1.0nM  Sodium Pyruvate (P5280, Sigma-Aldrich, Dorset, UK) 
10 ng/mL Recombinant Human TGF-β3 (#100-36, PeproTech EC Ltd., London, 
UK) 
5.0 x 10
5
 BMSC were centrifuged at 2000 rpm for 5 minutes in universal containers. 
The pellets were left at the bottom of the universal containers and 10mL chondrogenic 
media was added. The lids of the containers were left loosely screwed on to permit gas 
exchange. The pellets were cultured in a standard humidified incubator, at 37°C with 5 
% CO2 (Nuaire DH Autoflow, Triple Red Laboratory Technologies, Long Crendon, 
Buckinghamshire, UK). After 24 hours, the pellets rounded up into small spheroid-
shaped pellets. These pellets were cultured for 21 days, with media changes every 3-5 
days, using supplemented chondrogenic media. After this time, the pellets were frozen 
in Tissue Tek
®
 OCT compound (sakura Finetek, Zoeterwoude, Netherlands), and stored 
at -20°C. 10µm cryosections were made of the pellets, using a cryosectioning machine 
(Bright Instrument Company, Huntingdon, UK) at -20°C, and mounted onto 1.0-1.5 mm 
thick glass slides (BDH, UK) and stored at -20°C. 
Chondrogenesis was investigated by Alician Blue and Sirius Red Histochemistry. 
 
2.2.11 BMSC Passage Number 
For osteogenic, adipogenic and chondrogenic differentiation, cells of passage four were 
used.  
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2.2.12 Histology-Osteogenesis 
Von Kossa Assay 
Von Kossa stain is used to detect mineral formation. As described above, cells were 
cultured on coverslips in osteogenic media. After 28 days, the culture media was 
discarded and the coverslips were washed with PBS and fixed in methanol for 10 
minutes. The coverslips were then gently washed with distilled water three times and 
incubated in 1.5 % silver nitrate (762000, Hopkin & Williams, UK) for one hour. 
During this time they were placed under a source of light, which promotes the reduction 
of Ca
2+
 ions in the presence of silver nitrate. The coverslips were gently washed 3 times 
with distilled water after the silver nitrate was discarded. The coverslips were then 
covered with 2.5% thiosulphate (Fisions Scientific Apparatus, Loughborough, UK) for 
5 minutes and gently washed with distilled water. Neutral Red (x634, Sigma-Aldrich, 
Dorset, UK), which stains nuclei red was used to counter stain the specimen for 5 
minutes. Distilled water was used to rinse off excess stain until the coverslip was clear. 
Photos were taken using an Olympus BH2 photographic microscope and a JVC KY 
F55B Colour Video camera using zeiss Ks300 software (Imaging Associates, Thame, 
UK). Coverslips pre-treated with 5% acetic acid for 2 minutes acted as controls. 
 
ALP quantitative biochemical assay (Cobas Bio)  
A commercially available kit (AP307, Randox Laboratories, Antrim, UK) was used for 
quantitative analysis. The working reagent was prepared by mixing pre-weighed p-
nitrophenol powder with 10 mL of diethanolamine buffer and heating the mixture to 
37°C. Cell culture samples in media were washed in PBS and treated with autoclaved, 
distilled water at 37°C (a hypotonic solution) to lyse the cells. Samples were frozen and 
thawed three times and centrifuged at 10,000 rpm for 10 minutes. 50 µL of the resultant 
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supernatant was loaded into Cobas Bio
®
 blue sample cups (AS diagnostics, Blackpool, 
UK). 0.25 mL of the p-nitrophenol phosphate working solution was added to each 
sample. The reagent and samples were loaded into the Cobas Bio
®
 analyzer (Roche 
Lewes, UK) to run the assay. ALP activity measurements were expressed as U/L.  
 
To compare results within groups, ALP activity readings were normalised for the 
number of cells by measuring the amount of DNA in each sample. This was done using 
the fluorometric dye Hoechst 33258, which binds specifically to the adenine-thymidine 
base pairs of DNA (Rago et al., 1990), (Rao and Otto, 1992). For the assay, lysed 
samples were transferred from cell culture dishes to Eppendorf tubes, which were spun 
in an ultracentrifuge at 10,000 rpm for 10 minutes, and the supernatant transferred to 
fresh tubes. A standard curve was prepared in a Fluoronunc
®
 96-well plate (Nunc, 
Rokskilde, Denmark), by diluting a stock, 1 mg/mL DNA standard (from calfthymus, 
D3664, Sigma-Aldrich, Dorset, UK) in saline sodium citrate (SSC) buffer, to 20, 10, 5, 
2.5, 1.25, 0.625 and 0.3125 µg/mL, and loading 100 µL of the standards into the 96-
well plate in triplicate. To prepare 500 mL of a 20x stock SSC buffer (20x the working 
concentration), 87.65 g of sodium chloride and 44.1 g of trisodium citrate was dissolved 
in distilled water and the pH was adjusted to 7.0 with 1M HCl or 1M NaOH. 
 
A map of the 96-well plate was made to record the standard/sample order. 100 µL of 
each sample was loaded into the plate in duplicate. The Hoerchst 33258 dye (B2883, 
Sigma-Aldrich, Dorset, UK) was diluted from 1.0 mg/mL to 1.0 µg/mL in SSC and 100 
µL added to each standard or sample well in the Fluoronunc
®
 plate. Samples were run 
in a Fluoroskan Ascent
®
 fluorimeter (Labsystems, Finland), using Genesis version 2.19 
(Life Sciences UK Ltd.,) and Ascent Research Edition version 1.1.1 software 
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(Labsystems, Finland). The adenine-thymidine-Hoercht 33258-specific fluorescence 
was read at 460 nm. From the standard curve, the DNA concentrations could be 
calculated. For this, Microsoft Excel was used to plot the known concentration of the 
standards versus their absorbance at 460 nm, and a linear equation fitted to the resulting 
line. Equations having a correlation coefficient of 0.95 or above were acceptable for 
calculating the DNA concentrations of the samples. 
 
ALP activity (U) per µg DNA was calculated as follows: 
ALP activity (U/L) =  ‘[ALP activity (U/mL)/100] 
Sample DNA concentration x 0.05 mL (volume of sample used for ALP assay) 
 
2.2.13 Histology-Adipogenesis  
Oil Red ‘O’ stain 
A stock Oil Red 'O' solution was prepared by dissolving 0.5 g of oil red ‘O’ in 500 mL 
isopropanol and warming the bottle for 30-60 minutes at 56°C. A working solution was 
made by diluting 30 mL of the stock solution in 20 mL distilled water. After 14 days in 
adipogenic media, cells were fixed in neutral buffered formalin for 10 minutes, after 
which they were washed with distilled water and then stained in Oil Red 'O' for 10 
minutes. After staining, cells were washed in distilled water and then counterstained 
using Harris' haematoxylin for 1 minute. 
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2.2.14 Histology- Chondrogenesis 
Alician Blue and Sirius Red Histochemistry 
To prepare the Alcian Blue stain, 1 g of Alcian Blue powder was dissolved in 100 mL 
of 3% acetic acid, and the solution filtered. The Sirius Red stain was prepared by 
dissolving 0.5 g of Sirius red F3B in 45 mL of distilled water. Absolute ethanol (50 mL) 
was then added, followed by 1.0 mL 1% sodium hydroxide. The solution was mixed 
vigorously, adding 4.0 mL of 20% sodium chloride, and the solution left to stand 
overnight before being filtered. Slide-mounted cryosectioned samples were fixed with 
methanol, after which they were washed in distilled water. They were then incubated 
with the Alcian Blue stain for 5 minutes, washed with distilled water, and then 
incubated in the Sirius Red stain for 1 hour.  
 
2.3 Results 
 
2.3.1 BMSC in Osteogenic media 
Von Kossa assay-Visual Observation and Qualitative Analysis 
After 28 days, those BMSC treated with osteogenic media had a greater positive 
reaction than those BMSC grown in normal media, with black deposits (Figure 2.1) 
indicating sites of mineralisation. Over 28 days, a multilayer of cells eventually formed 
three-dimensional folds, resulting in retraction of cells on the plastic surface and, thus, 
empty pockets of culture plastic became available for cell proliferation, similar to that 
noted by Schecroun and Delloye in 2003. There were no distinct changes in cell 
morphology over the 28 days. Negative control samples formed by low-passage BMSC 
treated with 5% acetic acid were negative for Von Kossa stain. 
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ALP Biochemical Assay  
The levels of ALP (Figure 2.2) were significantly higher at days 7 (p =0.05) and 21 (p = 
0.05) when cultured in osteogenic media compared to standard supplemented media. On 
day 7, ALP activity in the BMSC grown in the osteogenic supplemented media was 
noted to be 12.61 ± 5.20 U/µg DNA, while the ALP activity in the cells grown in 
standard culture media was 2.35 ± 0.22 U/µg DNA. Similarly, the ALP activity was 
higher on day 21 in the osteogenic supplemented media (15.87 ± 8.97 U/µg DNA) 
compared to the standard media (1.52 ± 0.34 U/µg DNA). However, no significant 
difference was noted between the osteogenic supplemented media (8.31 ± 0.023 U/µg 
DNA and 1.26 ± 0.090 U/µg DNA) and standard media (7.92 ± 0.63 U/µg DNA and 
1.68 ± 0.15 U/µg DNA) on days 14 and 28.  
 
 
 
 
 
 
 
Figure 2.1 Von Kossa staining (10 x magnifications). Image on the left is low passage BMSC 
treated with 5% acetic acid whereas the image on the right is BMSC in osteogenic 
supplemented media. Note the calcium nodules staining black with Von Kossa stain 
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2.3.2 Adipogenesis 
Oil Red ‘O’ stain 
Over the 14 days, cells changed morphology, becoming less spindle-shaped and shorter 
with long extensions. The oil red ‘O’ stain indicated the increased presence of lipids 
after BMSC were treated for 14 days adipogenic medium, when compared to those that 
were cultured in standard media. Although it must be noted that there were some cells 
staining positively for this lipid stain in the untreated BMSC cultures, it was to a much 
lesser extent than the adipogenic cultures 
 
Figure 2.3 Red staining with Oil Red “O” stains confirming adipogenic differentiation of BMSC 
Figure 2.2 Graph illustrating ALP activity of cells at different time points. Maximum 
activity was seen at 14 days 
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2.3.3 Chondrogenesis  
After 21 days in culture, all cell pellet cryosections showed a positive Sirius Red stain. 
However, only those samples treated with chondrogenic supplements including TGF-3 
showed a positive reaction with Alcian Blue (Figure 2.4d). Sirius Red is a non-specific 
collagen stain, while Alcian Blue is specific to GAGs. These results are in contrast to 
chondrogenic media excluding TGF-3 and the control media containing only 
penicillin/streptomycin (Figure 2.4a). 
 
Collagen I was found to be expressed in all cell pellets. Additionally, those cell pellets 
treated in complete chondrogenic media with TGF-3 were found to express collagen II 
in small quantities. Although the collagen II stain had high background fluorescence, 
positive collagen II reactions could still be detected (Figure 2.4b, c-g). 
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d) 
b) 
f) 
c) 
a) 
e) 
g) 
Figure 2.4 Stained cryosections of BMSC grown in DMEM+ (a-c) or chondrogenic 
medium for 21 days (d-g): a and d are sections stained with Sirius Red and Alcian 
Blue; b and f are stained for collagen I; c and g are stained for collagen II; e is a DAPI 
fluorescent nu 
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2.4 Spraying of BMSC 
 
2.4.1 Methods and Materials 
 
2.4.2 Suspension of BMSC in fibrin glue 
As described above the BMSC were first isolated and expanded in culture until passage 
four. To suspend the cells in fibrin glue, they were trypsinised off tissue culture plastic 
after four passages and centrifuged to form a pellet. The pellet was resuspended in the 
thrombin component of fibrin glue at a concentration of 1.0 x 10
6
 cells/mL.  
The fibrin glue I used was Tisseel
®
 fibrin glue (Baxter Health Care Ltd., Newbury, 
Berkshire, UK). This glue consisted of four components: a vapour-heated Tisseel
®
 
powder component (100-130 mg protein, of which approximately 75-115 mg is human 
fibrinogen); a bovine aprotinin solution; a vapour-heated human thrombin powder (45-
55 mg protein containing about 500 IU
2 
active bovine thrombin); a calcium chloride 
solution. The Tisseel
®
 fibrinogen component was reconstituted in the aprotinin solution 
after a 10 minute incubation at 37°C in a device specifically created to heat fibrin 
components (Fibrinotherm
®
, Baxter Health Care Ltd., Newbury, Berkshire, UK). Ovine 
BMSC were put in a universal container and spun in a centrifuge at 2000 rpm for 5 
minutes. The supernatant was then discarded and the pellet at the bottom of the 
universal container was resuspended in the 1.0 mL of reconstituted thrombin. Each 
component was then loaded into a 1.0 - 2.0 mL syringe (included in the Tisseel
®
 
package) and snapped into a dual-syringe holder with attached plunger device.  
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A 16-gauge cannula fixed to the end of the dual-syringe system was used to eject the 
BMSC-fibrin combination. 
 
Figure 2.5 The dual syringe system used for spraying the BMSC suspended in fibrin glue is seen in 
the picture. Commercially available components of Tisseel® package is also shown. 
 
 
2.4.3 Spraying BMSC in fibrin glue and fibrin-cell plug formation 
To spray fibrin glue using this system, a Duploject
®
 (Baxter Health Care Ltd., 
Newbury, Berckshire, UK) spray set was used, which consisted of sterile plastic tubing 
which connected to a dual-syringe tip, allowing air to come into contact with the fibrin 
components as they came out of the syringe. The other end of the tubing was connected 
to a Fibrijet
®
 (Micromedics, Inc., St. Paul, Minnesota, USA) pressure gauge, in turn 
connected to a pressure pump. The Fibrijet was set to the desired pressure (1.0 Atm for 
the studies described in my thesis), and the plungers of the fibrin system pressed to 
allow release of sprayed fibrin onto the surface of the implants intra-operatively.  
 
The effect of fibrin glue on BMSC viability, metabolism, proliferation, and morphology 
when applied using a spray or cannula has been studied previously (Kalia, 2007). The 
technique of spraying or the use of cannula does not affect the viability, metabolism or 
proliferation of BMSC. 
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The effect of fibrin glue on oBMSC viability, metabolism, proliferation, and 
morphology when applied using a spray or cannula 
 
Viability 
To assess the viability or death of cells after spraying, the Live/Dead assay was used. 
For this experiment, 2.0 x 10
6
 cells/mL were suspended in thrombin and combined with 
fibrinogen, as described above, and 0.05 mL of each component was applied using a 
cannula, or with a pressurised spray, onto the tissue culture surface of Corning 6-well 
tissue culture plates. Cells were then incubated in media with 1.0 M calcein and 
ethidium homodimer each (Invitrogen Ltd.), for one hour. After this time, samples were 
rinsed in PBS and viewed under a confocal microscope (Leica SP2 AOBS system, 
Leica Microsystems UK Ltd.), using Leica Confocal Software (LCS version 2.61, Leica 
Microsystems UK Ltd.) in 200 m-thick sections, and were reconstructed in a 3D 
overlay using LCS Lite (version 2.61, Leica Microsystems UK Ltd.) software. Six 
samples were analysed per group. The four groups were: 1) oBMSC suspended in fibrin 
glue, applied with a cannula; 2) oBMSC suspended in fibrin glue, which was sprayed at 
0.5 Atm; 3) oBMSC sprayed in fibrin glue at 1 Atm; and 4) oBMSC in fibrin glue, 
sprayed at 1.5 Atm. The percentage of live cells was calculated by dividing the number 
of live (calcein AM positive) cells by the total number of live and dead (ethidium 
homodimer-positive) cells. Results were compared to oBMSC initially plated at the 
same concentration, but on tissue culture plastic and without fibrin glue. 
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Proliferation 
A thymidine-H
3
 incorporation assay was used to determine the proliferation of oBMSC 
in fibrin glue when applied via a cannula or sprayed at different pressures. For this 
assay, 0.1 mL of fibrin & BMSC was cannulated onto the surface or sprayed at 1 Atm 
onto the well surface of 6-well plates (Orange Plastics, Triple Red Laboratory 
Technology), and covered with 2 mL of standard DMEM+. Proliferation was measured 
from 0-24 hours, 24-48 hours and 48-72 hours. For the 0 - 24 hours group, 1.0 L of 
thymidine-H
3
 (GE Healthcare) was added for each 1.0 mL of media, and placed in a 
standard humidified incubator for 24 hours. The assay was repeated in triplicate for 
each treatment and results were compared to oBMSC seeded at the same cell numbers 
as the cells suspended in fibrin, but cultured without fibrin glue. 
After each 24-hour time point, cells were lysed with three repeated cycles of freeze-
thawing. In order to break down the fibrin for analysis, samples were then freeze-dried 
overnight, resuspended in 0.5 mL of 1% papain (Sigma-Aldrich Co.) in PBS and 
incubated at room temperature overnight on a gentle shaker.  
 
The Effect of Spraying BMSC in Fibrin Glue 
Observation of Fibrin glue spraying at different pressures 
Fibrin application at 1.0 and 1.5 Atm was visibly easier, smoother and more evenly 
distributed when compared to spraying fibrin at 0.5 Atm. At this pressure, the fibrin 
glue did not have sufficient pressure to properly form an aerosol. 
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Viability 
There was no significant difference in the viability of cells after spraying at 0.5 Atm, 
1.0 Atm, or 1.5 Atm in fibrin glue. Calcein was spread intracellularly, while the 
ethidium was visualised in the nucleus/nucleolar region of the cell. In all samples, some 
cells were seen to stain positively for both calcein AM and ethidium homodimer, 
suggesting plasma membrane damage that allowed ethidium penetration or cell death 
within minutes after spraying. The mean percentage of live cells in the groups sprayed 
at 1.5 Atm was 52.26  5.08 %, while for the cells applied by a cannula, the mean 
percentage of live cells was 59.82  13.36 % (Figure 8a). There was no significant 
difference between all groups (p > 0.05 in all comparisons). 
 
Proliferation 
Samples grown without fibrin glue (BMSC only) appeared to have less proliferation 
than those samples in fibrin glue applied with a cannula at 24 and 48 hours (35.95  
4.74 Bq/g DNA/hour and 36.20  11.06 Bq/g DNA/hour in the oBMSC-only group; 
79.33  8.61 Bq/g DNA/hour and 70.66  7.73 Bq/g DNA/hour in the cannula 
group). Cell proliferation was reduced after 24 hours in samples that had been sprayed, 
compared to cannula-applied controls (63.93  6.00 Bq/g DNA/hour at 24 hours, 6.61 
 0.90 Bq/g DNA/hour at 48 hours and 7.56  1.81 Bq/g DNA/hour at 72 hours; see 
Figure 8b). The difference in values were significant at 24 and 48 hours between the 
BMSC-only and cannula groups (p = 0.01, p=0.03 at 24 and 48 hours, respectively), at 
24 hours between the BMSC-only and spray groups (p=0.02), and at 48 hours between 
the cannula and spray groups (p=0.03). Cell proliferation was reduced in all samples at 
72 hours (19.32  11.89 Bq/g DNA/hour; 3.78  0.66 Bq/g DNA/hour; and 7.56  
1.81 Bq/g DNA/hour, in the oBMSC-only (control, cannula and spray groups, 
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respectively). There was no significant difference between groups at this time point (p > 
0.05 for all group comparisons). 
 
Figure 2.6 A) Chart indicating the percentage of live (Calcein AM positive) oBMSC in fibrin glue 
after being ejected from a cannula or using a spray, at 0.5 Atm, 1.0 Atm, and 1.5 Atm. B) Bar 
graph comparing 3H-thymidine incorporation (indicative of proliferation) 
 
2.5 Discussion 
 
This chapter confirms the ability of the cells isolated from the bone marrow aspirate to 
differentiate along osteogenic, adipogenic and chondrogenic lineages. The BMSC 
derived from the bone marrow were plastic-adherent cells that formed characteristic 
CFU-Fs and had a fibroblastic morphology.  
 
For confirming the differentiation potential of the BMSC along osteogenic pathways, 
ALP assay and Von Kossa stains were used. Oreffo, et al. (1998) used the ALP assay to 
show osteoblastic differentiation of human BMSC. The ALP assay looks at ALP 
activity of a cell lysate but ALP on osteoblasts is expressed on the cell membrane. 
There exist a few different isoforms of ALP which are expressed in various tissues, such 
as the kidneys, liver and bone (Nakayama et al., 1998). Specific ALP antibodies have 
been used to show cell surface expression of ALP (Rust, 2004), (Gronthos et al., 1994), 
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although it has been suggested that the post-translational modifications to the 
carbohydrate side chains of the different ALP isoforms may not be easily detectable by 
commercially available antibodies (Nakayama et al., 1998).  
 
The Von Kossa stain showed calcium deposition by the cells grown in osteogenic 
supplemented media. Similar results were noted in studies by Janssen et al. (2006) and 
Gorustovich et al. (2002). 
 
The surfaces used to culture the cells described in this chapter as well as the surfaces 
used during differentiation, were slightly different in some cases. For example, 
Thermanox® coverslips were used to culture oBMSC in osteogenic media to show 
mineralisation after 28 days using the Von Kossa stain, whereas 6-well plates were used 
to culture cells for the ALP assay at 7, 14, 21 and 28 days. Each plastic surface is 
fabricated from different materials, and uses different techniques to treat the surface 
whether it is by using an electrostatic charge, or etching methods (EMS Catalog, 2007; 
(Scholz, 2003). This may, in turn, have resulted in varying conditions and reactivity to 
the differentiating supplements.  
 
In future, other useful tests that could be used to characterise BMSC are a surface 
marker profile as well as to look for mRNA expression of genes involved in the 
different differentiation pathways, such as osteocalcin, osteopontin, ostrix, PPARy2, 
and collagen type II and X, and aggrecan (Lisignoli et al., 2006). One method that has 
been used to a lesser extent in the characterisation of BMSC is analysis of many 
different genes using a gene chip (Bourne et al., 2004); (Hishikawa et al., 2004).  
 
It is unknown whether or not the anaesthetic regime used during bone marrow 
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aspiration affected the isolation, viability, or phenotype of the BMSC isolated from 
sheep. Halothane does not immediately exit the body, staying dissolved in fat and other 
tissues after the cessation of the anaesthetic regime. Also, the bone marrow was treated 
with 500IU of heparin per sample, in order to prevent clotting. The effects of heparin on 
BMSC or bone marrow cells has not been extensively reported in the literature, 
although it has been suggested that heparin-binding domains found in various elements 
of the extra-cellular matrix and the cell surface composition might affect cell signalling 
(Beauvais and Rapraeger, 2004); (Lopes et al., 2006). Also, the animals were under 
general anaesthesia with an inhaled anaesthetic (halothane) while bone marrow 
aspirates were taken. Bone marrow contains fatty tissue which can accumulate 
hydrophobic halothane molecules (Martin, 1994), which may in turn affect the BMSC. 
However, studies show that the first tissues to be exposed to halothane are those that 
receive a high fraction of cardiac output. The bone marrow is well vascularised, so a 
certain percentage of halothane probably did reach those cavities in the short term, even 
though the animals were not under anaesthetic for extended periods of time (time 
ranging from 10-45 minutes). Halothane has been shown to be carcinogenic in vitro, 
although one report did describe an increase in cancer cases in anaesthetists who had 
been repeatedly exposed to waste anaesthetic gas, as well as a rise in congentital 
abnormalities and spontaneous abortion (Martin, 1994). It is, therefore, possible that 
halothane could cause mutagenesis in the BMSC, or be accumulated in liposomes or 
any other lipid-containing structure in the cell for some length of time, before breaking 
down into its metabolic derivatives.  
 
The experiments described in this paper show that BMSC survive spraying in fibrin 
glue at 1 atm. With regard to the spraying of cells in fibrin glue, it is unknown whether 
or not shear stress and fluid flow experienced by the cells in fibrin instigates an effect 
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on the cells differentiation or programmed cell death (apoptotic) pathways. Shear stress 
has been shown to induce osteocalcin expression in rat BMSC (Kreke and Goldstein, 
2004) and may aid in the osteogenic differentiation of cells. In the Live/Dead 
experiment presented in this paper, some cells appeared to undergo cell death minutes 
after spraying, having first reacted with the “live” cell marker calcein AM to produce 
fluorescent calcein molecules. Whether or not this is apoptosis or necrosis due to 
irreversible cell damage could be determined by using apoptosis assays such as the 
terminal transferase dUTP nick end labelling (TUNEL) assay, which detects the DNA 
degradation step in apoptotic cells (Gavrieli et al., 1992), or protein detection methods 
such as immunohistochemical staining or western blotting for apoptotic markers such as 
Annexin V, Bax or p53 (Loewe et al., 2006), (Basu and Haldar, 1998). However, those 
oBMSC that do survive actively metabolise and proliferate, as shown using Alamar 
Blue and Thymidine-H
3
 incorporation. Spraying did affect cell metabolism after the 
first 24 hours post-spraying, but cells appear to have recovered by Day 2 of the 
experiment. To look at the effects of spraying in fibrin glue on oBMSC osteogenic 
differentiation, one could perform RT-PCR detection of early osteoblastic genes such as 
cbfa-1 or osterix (Krishnan et al., 2003), (Pittenger et al., 1999). 
 
Currie, et al. (2003) found no significant difference between spraying keratinocytes onto 
freshly debrided porcine wound sites in fibrin glue or without (cells suspended in 
culture medium) on the epithelial areas after three weeks in vivo. 
 
In conclusion, this chapter summarises the isolation, expansion and characterization of 
BMSC along osteogenic, chondrogenic and adipogenic cell lineages. This confirms the 
multipotency of the isolated cells. Secondly, the technique of spraying the BMSC 
suspended in fibrin glue has no effect on the viability, metabolism or proloferation of 
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BMSC.  
Thus, BMSC isolated from bone marrow aspirate may be differentiated along the 
osteogenic pathway by culturing them in osteogenic supplemented media and they can 
be suspended in fibrin and applied on to the surface of orthopedic implants by pressure 
controlled spraying techniques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 80 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  
3. Augmenting the Fixation of Uncemented Press-Fit 
Acetabular Cups in Total Hip Replacements Using 
Bone Marrow Stromal Cells (BMSC) Suspended 
in Fibrin Glue. 
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3.1 Introduction 
This chapter investigates whether or not spraying autologous BMSC suspended in fibrin 
glue on the surface of HA-coated press-fit acetabular cups would increase bone 
formation and bone-implant osseointegration. A caprine hybrid THA model has been 
used for this study. Results of Chapter 2 confirm that BMSC sprayed on implant 
surfaces are viable and have the ability to proliferate and differentiate.  
 
The hypothesis of this chapter is that: 
Spraying autologous BMSC in fibrin glue onto the surface of HA-coated, press-fit 
acetabular components would increase bone formation around the implant, 
improve bone-implant contact, and reduce fibrous tissue at the bone-implant 
interference compared to fibrin glue-treated controls in a caprine model. 
 
The aims and objectives of this chapter 
1) To spray BMSC at a concentration of 10 x 106 cells in fibrin glue onto the outer surface 
of HA-coated press-fit acetabular cups of THAs in an in vivo caprine model; 
2) To use force plate analysis to differentiate loading of operated and non-operated limbs  
and to compare between  the study and control group; 
3) To quantify the new bone formation at the implant bone interface using histological 
techniques and compare this in the study and control group; 
4) To quantify the bone-implant contact along the interface by histological techniques and 
compare this in the study and control groups. 
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3.2 Materials and Methods 
 
3.2.1 Animal model selection 
Sannan goats were selected for this study. These animals were skeletally mature (two to 
five years of age), and weighed between 65-90 kg. All procedures were carried out 
according to the Home Office Animals Scientific Procedures Act of 1986.  
 
3.2.2 Procedure for BMSC isolation and characterisation 
Animals were cared for as described in Chapter 2. BMSC were isolated, culture 
expanded and characterised as described in Chapter 2. The BMSC were differentiated 
along osteogenic, chondrogenic and adipogenic pathways to confirm multipotency. 
 
3.2.3 Suspension of BMSC in fibrin glue and the technique of spraying 
BMSC on orthopaedic implants 
The suspension of BMSC in fibrin glue and the technique of spraying BMSC on the 
surface of implants are detailed in Chapter 2. BMSC were prepared as described in 
Chapter 2. On the day of the surgical procedure, 10 x 10
6 
BMSC were suspended in 1.0 
mL of reconstituted thrombin. 
10 x 10
6
 cBMSC were suspended in reconstituted thrombin (Tisseel, Baxter Health 
Care Ltd.). The Tisseel components were assembled in the operating theatre per-
operatively. 
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The technique of spraying BMSC and suspension in fibrin does not affect the viability, 
metabolism or proliferation of BMSC (Chapter 2 section 2.4.3). 
 
3.2.4 Experimental groups 
Two groups were studied. Twelve goats underwent total hip replacements and were 
randomly assigned to the two groups. 
Control Group: Total hip replacement with cemented femoral components and press-
fitted, HA-coated acetabular components sprayed with fibrin glue (WITHOUT 
CELLS); 
Experimental group: Total hip replacement with cemented femoral components and 
press-fitted, HA-coated acetabular components treated with 10 x 10
6
 BMSC in a fibrin 
glue spray. 
 
3.2.5 Implant Design & manufacture 
Custom made goat implants (total hip replacements) were manufactured for this 
experiment. Titanium alloy (TiV4Al6) was used to manufacture the femoral component 
for cemented fixation and acetabular cup for uncemented fixation was used (Figure 3.1). 
The acetabular cups were coated with a layer of HA approximately 50m in thickness 
using a plasma spray technique (Plasma Biotal Ltd. Tideswell, North Derbyshire, UK). 
Each cup had eight cutting flutes equally spaced around the periphery of the cup to 
provide rotational stability after fixation. The femoral head was made of cobalt 
chromium and polyethylene acetabular cup liners were used. 
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3.2.6 Surgical Procedure 
All animals were handled and cared for as described in Chapter 2 (Materials & 
Methods). The pre-operative preparation and anaethesia are as described in Chapter 2 
also. For total hip replacement, right hips were routinely used in all case. The region 
over the greater trochanter was prepared for surgery using povidine-iodine solutions as 
previously describe in section 2.   The animals were placed on their left side on the 
operating tables and a posterior approach was used to access the hip joint. Once 
dislocation had been achieved, a femoral neck osteotomy was performed, and the 
femoral head excised. The acetabulum was then prepared using reamers of increasingly 
larger sizes until the desired equatorial diameter was achieved, and bleeding 
subchondral bone was uncovered. 
In the experimental group animals, 2 ml of autologous BMSC in fibrin glue was sprayed 
Cutting flute on 
acetabular component 
Acetabular 
component 
Femoral component 
Figure 3.1 Diagram of total hip replacement used 
in caprine model, which included a cemented 
femoral component and an uncemented 
acetabular cup with an ultra high molecular 
weight polyethylene liner. 
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onto the HA-coated surface of the acetabular cups at 1.0 atm of pressure. To do this, the 
fibrinogen and thrombin components of the fibrin glue were transported to the operating 
theatre with or without BMSC (see Chapter 2) and maintained at 37° C in a Baxter 
Fibrinotherm
®
 device (Baxter Health Care Ltd., Newbury, Berkshire, UK) until used. 
Each component was loaded into a 1.0 mL syringe (included in the Tisseel package) and 
snapped into a dual-syringe holder with attached plunger device.  
To spray the fibrin glue using this system, a Duploject® (Baxter Health Care Ltd., 
Newbury, Berkshire, UK) spray set was used, which consisted of sterile plastic tubing 
which connected to a dual-syringe tip, allowing air to come into contact with the fibrin 
components as they came out of the syringe. The other end of the tubing was connected 
to a Fibrijet
® 
(Micromedics, Inc., St. Paul, Minnesota, USA) pressure gauge, which was 
connected to a pressure pump (see Chapter 2). The Fibrijet was set to 1 atm and the 
plungers of the fibrin system allow release of aerolised fibrin onto the surface of the 
HA-coated implant. The implants were slowly turned as the fibrin was applied, to allow 
an even distribution around the surface of the cup collar (figure 3.2).  
For implants in the study group, the acetabular shell was coated in a layer of 2 ml fibrin 
glue containing 10 x 10
6 
BMSC (Figure 3.2). After three minutes, once the fibrin was 
firmly set, the acetabular component was impacted into position. At this point, some 
fibrin glue would be squeezed out around the rim of the cup and was observable by eye.  
 
 
 
 
 
 Figure 3.2 Photograph of a caprine acetabular cup which has been 
coated with a fibrin glue spray. 
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In the control group only fibrin glue was sprayed before the cup was impacted into 
position.  
The femur was then prepared by first removing trabecular bone with a curette, and 
repeatedly washing with normal saline solution (0.9% sodium chloride solution). A 
cement restrictor was inserted in the femoral canal. Bone cement (Refobacin

 Bone 
Cement, Biomet Europe) was then applied and pressurised into the canal, prior to 
insertion of the femoral component. Once the cement had set, the hip was reduced, and 
the tissue sutured.  
A spray bandage (Opsite®, Smith & Nephew, Gallows Hill, Warwick, UK) was applied 
to the wound. Antibiotic and analgesic prophylaxis was administered daily with 
subcutaneous injections of Exenel™ (ceftiofur hydrochloride, 1 ml/50 kg, Pfizer Inc.) 
and IM injections of Vetergesic™ (buprenorpine, 0.6 mg/animal, Reckitt and Colman 
Products Ltd.,) for three days post-operatively.  
 
3.2.7 Post -operative radiographs 
Post-operative radiographs were routinely taken to assess the position of the 
components and to look for the presence of any intra-operative fractures (see Figure 
3.3). 
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3.2.8 Measurement of Ground Reaction Force 
To compare the function of the operated limb between groups, the ground reaction force 
was measured at 3, 6, and 12 weeks post-operatively. Animals walked over a force plate 
and the force transmitted through the operated (right) and unoperated (left) limb was 
recorded. The maximum force was recorded (Fmax) and expressed as a percentage of 
force through the right limb compared to the left limb, or Fright max/Fleft max. 
Animals were sacrificed with an overdose of 20% pentabarbitone (0.7 mg/kg, J.M. 
Loveridge Ltd. Southampton, UK). 
 
3.2.9 Undecalcified Hard-Resin Histology 
Following sacrifice, all right acetabulae were prepared for histology by stripping excess 
soft tissue and fixing in 10% neutral buffered formalin (NBF) for a minimum period of 
Figure 3.3 Radiograph showing caprine THA in situ post-
operatively 
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one week. Specimens were dehydrated in increasing concentrations of industrial 
methylated spirit (IMS). Samples were de-fatted in chloroform and immersed in a 50% 
IMS, 50% resin mixture (LR White Resin, London Resin Company Ltd., Reading, 
Berkshire, UK), followed by immersion in 100% resin. Samples were then cast using a 
polymerisation accelerator (LR White Accelerator, London Resin Company Ltd., 
Reading, Berkshire, UK). Specimen blocks were sectioned at four sites, using a water-
cooled band saw with a diamond-edged blade (Exact saw, Germany). Thin sections 
(approximately 80 µm thick) were prepared (Exact grinding machine, Germany; and 
Exact Polishing machine, Germany) and stained with Toludine Blue (Bancroft and 
Stevens, 1986) and Paragon (Tanzer et al., 2003) to stain soft tissue and bone, 
respectively. Stained slides were then viewed under an Olympus light microscope and 
images digitally captured using a JVC KY F55B Colour Video camera. Bone area and 
bone-implant contact was quantified using image analysis software (Zeiss KS300 
software, Imaging Associates, Thames, UK). 
 
3.2.10 Bone Area 
New bone area adjacent to the cup was measured using a line-intersection method, 
where four lines radiating from the centre of the cup were used to divide the cup area 
into five zones (see Figure 3.4a). New bone area was quantified outwards from the cup 
within 1 mm
2 
of the surface within the 5 zones, and was quantified in units of mm
2
.  
 
3.2.11 Bone-Implant contact 
A line intercept method was employed to measure the bone implant contact where the 
presence of bone at the interface was measured at the intersection of 34 lines radiating 
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from the centre of the radius of the cup (Figure 3.4b). Bone implant contact was 
expressed as a percentage.  
 
3.2.12 Fibrous Tissue measurement 
Where present, the thickness of the fibrous tissue from the metal backing to the bone 
surface was measured along the radiating line. 
For the purpose of analysis, the 5 zones around the cup and 35 regions were also 
grouped into two categories: the periphery and the dome of the cup. 
 
3.2.13 Statistics 
To test the normality of the distribution of the data, the Kolmogorov-Smirnov test was 
used, using SPSS 11.0 for Mac OSX. Parametric data was analysed using an 
independent-samples T test; non-parametric data was analysed using the Mann-Whitney 
U test. Results were considered significant when p < 0.05. 
 
5 
zones 
1 
2 
3 
4 
5 
35 zones 
1 35 
a b 
Figure 3.4 a) Diagram of acetabular cup divided into 5 zones for quantification of new bone formation at the 
bone-implant interface; b) Diagram of acetabular cup divided into 35 zones for analysis of bone-implant 
contact and fibrous tissue thickness. 
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3.3 Results 
 
3.3.1 Post-operative Results 
Animals were allowed immediate mobilisation and all were fully weight-bearing within 
48 hours. All twelve animals were weight-bearing and healthy for the 12-week period.  
 
3.3.2 Measurement of Ground Reaction Force 
Pre-operatively, goats were tested for their Ground Reaction Force at 6 and 12 weeks. 
When data was expressed as the percentage loading of the operated (right) leg compared 
to the un-operated (left) leg, there was no significant difference in loading between 
groups at both 6 weeks (Controls-79.74  3.63%, BMSC-59.39  9.33%, p=0.086) and 
12 weeks (Controls-86.0%  2.85%, BMSC-62.33  5.12%, p=0.055). Figure 3.5 
displays these results. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Graph displaying force plate analysis results at 6 and 12 weeks. 
Results were normalised to pre-operative loading values (100%). 
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3.3.3 Macroscopic analysis at retrieval  
Upon retrieval of the acetabular components, four of the six acetabular cups sprayed 
with BMSC group had a noticeable cuff of bone formation over the rim of the cups. 
None of the cups with sprayed cells were loose. Out of the six implants in the control 
group, two of the acetabular cups appeared loose (that is, were not firmly attached to the 
acetabulum by tissue). 
 
3.3.4 Histology 
In BMSC-group sections, a thick layer of bone in contact with the acetabular cup 
surface could be seen, with little fibrous tissue present (Figure 3.6b). This was in 
contrast to the control group, which had a fibrous tissue layer interposing between the 
bone and implant surface, and as a result, less bone-implant contact (Figure 3.6a).  
 
 
 
 
 
 
 
 
New Bone Formation 
New bone formation in Zone 5 showed a significant increase in the BMSC group 
(71.9710.91%), when compared to the controls (23.8515.13%, p=0.028, Figure 3.7). 
The other zones did not show a significant difference in new bone around the cup. 
B 
F 
I 
A 
I B 
  B 
Figure 3.6 Histological sections showing the acetabular cup-bone interface 
in the A) control group, and B) BMSC-treated group. 
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Overall, new bone growth in the BMSC group was 30% greater than the control group 
(71.428.97% and 54.2216.56%, respectively, p=0.58). 
 
 
 
 
 
 
 
 
 
 
 
 
Bone-Implant Contact 
Overall, bone-implant contact was significantly increased in the BMSC group (30.71  
2.95%), in contrast to the control group (5.14  1.67%, p=0.014). When this was 
divided into two regions, the periphery and dome of the cup, it was found that bone-
implant contact was significantly increased in BMSC-treated cups around the periphery 
of the cups (34.29  11.61%), when compared to controls (7.14  2.61%, p=0.01, 
Figure 3.8). However, there was no significant difference in bone-implant contact at the 
dome of the cup between the two groups (19.84  16.19% in the control group, 20.95  
5.75% in the BMSC-treated group, p=0.165). 
Figure 3.7 Bar graph displaying new bone formation (%) in each of the 5 zones 
around acetabular cups in control and BMSC-treated groups. 
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3.3.5 Fibrous Tissue Analysis 
Fibrous tissue thickness at the periphery of the cups was significantly reduced in 
BMSC-treated group cups (327.4920.38 mm), in contrast to control group cups 
(887.21  158.89 mm, p=0.02, Figure 3.9a). There was no significant difference in 
fibrous tissue thickness found at the dome of the cup (902.45  80.67 mm in the control 
group and 739.1  173.72 mm in the BMSC group, p=0.47, see Figure 3.9b). 
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Figure 3.8 Graph showing bone-implant contact around the periphery and dome of 
cups in both experimental groups. 
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3.4 Discussion 
 
BMSC suspended in fibrin glue and sprayed on the surface of HA-coated acetabular 
cups increase bone implant osseointegration and bone implant contact and decrease 
fibrous tissue at the bone implant interface. 
Hydroxyapatite (HA) coatings have been used on orthopaedic implants to promote 
fixation in the host bone (Blunn et al., 2000), (Coathup et al., 2005), (D'Antonio et al., 
1992); (Geesink, 1993). Clinically, HA coatings are used extensively on femoral and 
Figure 3.9 A) Plot of fibrous tissue length across all 35 acetabular 
zones comparing control and BMSC-treated groups. B) Mean fibrous 
tissue thickness around the acetabular 
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acetabular THA components (Froimson et al., 2007), (Overgaard et al., 1999), (Capello 
et al., 2006). HA coatings have also been applied to uncemented massive bone tumour 
prosthesis, where they have improved implant fixation and contributed to enhanced 
implant survival (Unwin, 2005). In large animal models, these coatings have been 
shown to improve osseointegration of the implant to host bone and prevent wear particle 
migration (Coathup et al., 2005), (Geesink et al., 1988). Geesink, et al. (1988) showed 
that in a canine model that femoral components with HA coating and left in situ for 10.6 
years, there was no evidence of wear debris-associated osteolysis. A study by Coathup, 
et al. (2005) comparing different surfaces and their effects on bone-implant contact and 
the prevention of wear-particle migration in an accelerated wear ovine model found that 
a porous, HA-coated surface was most effective. 
HA is osteoconductive (Geesink et al., 1988), and has been shown to promote the 
accumulation of bone morphogenetic proteins (Geesink, 2002). To promote 
osteoinductivity, HA has been combined with bone morphogenetic protein 2 (BMP-2) 
and has been proven to improve bone growth and implant fixation in animal models 
(Sachse et al., 2005), (Aebli et al., 2005). It may also be possible to promote early 
fixation and increase bone implant contact around implants such as the acetabular 
component of total hip replacements by treating the implant surface with osteoblast 
precursor cells such as bone marrow stromal cells (BMSC). This may prevent the 
migration of wear particles to the bone-implant interface and reduce longer-term aseptic 
loosening. This chapter describes a BMSC-fibrin spray technique, developed in order to 
apply cells to the implant surface and the effect of using this on acetabular implant 
fixation in a large animal model.  
With regard to the in vivo experiment reported in this paper, there was no significant 
difference in loading of the operated legs between groups, indicating that function has 
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not been compromised by the addition of BMSC, and that the results are not associated 
with better recovery or increased loading of one group compared to the other. 
 
 A radiographic evaluation would be useful in future studies, as well as a longer-term 
investigation looking at the effectiveness and survival of BMSC over a greater period of 
time. It has previously been reported (Coathup et al., 2005) that improved fixation 
reduced osteolysis at the bone-implant interface, and that the fixation was greatest when 
a porous HA coating was used on the uncemented acetabular cup. The HA-coated, grit-
blasted group that was included in the study did not perform as well as the porous HA-
coated cups, and was, therefore, selected for this study as being a less-than-perfect 
situation where improved cup fixation would be beneficial. 
It may also be beneficial to apply the BMSC-fibrin glue system to HA-coated, 
uncemented femoral stems and in other situations where osseointegration of implants is 
important. A previous study by Kalia, et al. (2006) showed that when autologous, ovine 
BMSC were sprayed in fibrin glue over the HA-coated collars of mid-shaft tibial 
replacements used as a model of fixation of massive segmental bone tumour implants, 
the bone integration of the collar was improved when compared to controls. 
Bone formation was significantly increased around the periphery of the cup in the 
BMSC-treated group, when compared to controls, whereas, at the dome of the cup, 
there was no significant difference. A variation in cell distribution around the acetabular 
cups in the BMSC-treated group may account for this result, as fibrin was pushed out 
from the surface of the acetabular component towards the implant periphery. 
Subsequently, as the fibrin was combined with the BMSC, the cell numbers may have 
been higher at the acetabular cup periphery than at the dome.  
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Additionally, a variation in mechanical forces applied to the BMSC around the 
acetabular component may have influenced bone formation. Studies looking into the 
sensitivity of BMSC to mechanical forces (Nagatomi et al., 2003), (Hamilton et al., 
2004), (Ignatius et al., 2005) have shown that an application of compressive forces can 
cause osteoblastic differentiation of BMSC. Ignatius, et al. (2005) demonstrated 
increasing expression of the master osteoblastic gene CBFA-1 after mechanical 
stretching of a human osteoblast precursor cell line (hFOB 1.19). It has been proposed 
that this mechanical effect is regulated by the MAP kinase (MAPK) signalling pathway, 
using extracellular signal-regulated kinase 1/2 (ERK 1/2) (Simmons et al., 2004). When 
the press-fit cup was impacted into place in the goat, it is possible that the deformation 
of the cup and fit of the cup in the acetabula caused increased compressive forces closer 
to the periphery of the cup, inducing enhanced osteoblastic differentiation by the 
BMSC. Cutting flutes at the edges of the cup may have also altered the loading 
situation. It would be useful to measure the forces applied by the cup on the surrounding 
bone using telemetry, as has been done to measure joint contact forces (Graichen et al., 
1999), to see if this correlated with the pattern of increased bone formation around 
BMSC-treated cups. It may also be possible that the fibrin glue, once impacted into the 
acetabulum, may have migrated towards the periphery of the cup, along with the 
enmeshed cells, resulting in greater bone formation at this location simply because there 
was more fibrin present. This movement of the fibrin may be useful in improving the 
filling of gaps between the implant and bone, which is a property attributed to 
hydroxyapatite (Geesink et al., 1988), (Overgaard et al., 1999).  This property may be 
important for filling in defects around revision implants.  Also, increasing bone 
formation and decreasing fibrous tissue around the periphery of the cup could be 
effective in preventing the migration of wear particles between the bone-implant 
interface and the resulting osteolysis. Fibrous tissue is known to be a conduit of wear 
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particles, and previous work has shown that sealing the implant from wear particles 
using a non-resorbable, ePTFE membrane (Bhumbra et al., 2000) in a goat THA wear-
particle producing model was effective in preventing particle migration. 
In future, it would be useful to be able to track the implanted cells’ contribution to new 
bone formation around the implants, by using a marker such as GFP or LacZ (Zhou et 
al., 2005). It may be possible that the BMSC in this study promote bone growth in two 
ways, by direct differentiation into bone-producing osteoblasts, or by the release of 
cytokines that promote the homing of host cells to the site, and augment the bone 
healing response (Caplan and Dennis, 2006). 
 
3.5 Conclusions 
 
Spraying BMSC in fibrin glue onto HA-coated, press-fit acetabular cups significantly 
increased bone area around the implants, improved bone-implant contact, and reduced 
the amount of fibrous tissue around the cup. This study may have clinical implications 
as this technique may increase the early fixation and reduce osteolysis around 
acetabular components of primary THAs or hip resurfacing procedures, thereby, 
increase longevity of the implants. BMSC may also have a beneficial role in 
regenerating bone if applied to revision situations where poor bone stock is an issue.
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Chapter 4  
4. The Effect Of Guided Bone Regeneration And 
Varying BMSC Dosages On Osseointegration Of 
HA Coated Implants 
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4.1 Introduction 
 
The previous chapter has demonstrated the ability of BMSC to produce new bone and 
improve bone-implant contact in a large animal model. However, there may be an 
optimum BMSC dose required to stimulate maximum bone formation in vivo. It may be 
possible to stimulate the BMSC in an osteogenic supplemented media to improve bone 
formation. Guided bone regeneration techniques when combined with the cell 
therapeutic treatment investigated in my thesis may further enhance bone formation. 
Expanded-polytetrofluoroethylene (e-PTFE, Gore-Tex™) facilitates new bone 
formation by sealing the defect site from the surrounding tissue (Bhumbra et al., 1998). 
E-PTFE is a biocompatible, non-resorbable, synthetic membrane that has been used in 
guided bone regeneration.  The membrane used in my study had three layers.   Its inner 
layer, which has 1 micrometer pores, prevents the in-growth of cellular material such as 
fibrous tissue, whereas water and various macromolecules and growth factors can pass 
through freely.  The outer layers are more porous and allow for tissue integration. This 
membrane can be used to increase bone regeneration into defects and the technique 
allows bone to grow directly around an implant (Bhumbra et al., 1998). E-PTFE has 
also been shown in a large animal model to effectively prevent wear-particle induced 
osteolysis at the acetabular cup implant-bone interface created by total hip 
replacements, significantly reducing the aseptic loosening of these implants (Bhumbra 
et al., 2000). The use of e-PTFE with various cell concentrations of BMSC in this study 
may prevent cell migration from their original site of implantation. 
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The hypotheses of this chapter are: 
1) There is an optimum cell concentration at which BMSC produce maximum new 
bone. 
2) Stimulating BMSC in osteogenic media should increase the quantity of new bone 
formation. 
3) Guided bone regeneration is possible using e-PTFE and BMSC. 
 
The aims and objectives of this chapter are:  
 
1) To investigate the effects of autologous BMSC in varying cell dosages (1.0 X 10
5
 
and 10 X 10
6 
BMSC/mL) as well as fibrin alone on the amount of new bone formation 
in a caprine trans-cortical model, within a 1.5 mm gap defect in a in vivo model.  
 
2) To investigate the effect of autologous BMSC treated in osteogenic supplemented 
media (10 X 10
6
 cells treated in osteogenic supplemented media) on the amount of new 
bone formation in the same model. The BMSC treated in osteogenic supplemented 
media were tested for osteoblastic differentiation as described in Chapter 2 (section 
2.2.12).   
 
3) To investigate the effect of using e-PTFE with the autologous BMSC on the amount 
of new bone formation in the same model.  
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4) To prepare histological sections and measure the amount of new bone formation 
adjacent to the implants and within the gaps. 
 
4.2 Materials and Methods 
 
Sannan goats were selected for use in this study. These animals were skeletally mature 
(two to five years of age), and weighed between 65-90 kg. All procedures were carried 
out according to the Home Office Animals Scientific Procedures Act 1986.  
 
4.2.1 Isolation and Expansion of autologous BMSC 
Caprine BMSC were isolated as previously described (See Chapter 2, Materials and 
Methods).Cells were expanded to passages 3 and 4 for use in this study. The BMSC 
were differentiated in osteogenic supplemented media (as described in Chapter 2, 
section 2.2.8 and the cells were tested for osteogenic potential (as described in Chapter 
2, section 2.2.12). 
 
4.2.2 Implant design and manufacture  
The implants were small partially-threaded transcortical screws similar to that used by 
Bhumbra, et al. (1998) and (Kalia, 2007). The implants were manufactured from 
titanium alloy (T.6A14V). The screws were 25 mm in length, and the distal M5 
threaded region was 5.0 mm in diameter. A cutting flute was located at the bottom for 
ease of insertion into the cortical bone. The top half of the screw was 3.0 mm in 
Chapter 4 
 104 
diameter and was plasma sprayed with a highly crystalline, thin (<50 micrometer 
thickness) HA-coating (Plasma Biotal, Tideswell, North Derbyshire, UK).  
 
4.2.3 Treatment groups  
Four implants were inserted into the left and right tibia of each sheep, with a total of 
eight implant groups per sheep. The centres of the drilled holes were 3 cm apart in all 
cases. An e-PTFE covering the implant and defect at the near cortex was used on the 
right leg, while no e-PTFE was used on the left leg. Butyl-cyanoacrylate glue 
(Vetbond™, National Veterinary Supplies. Talke Pits, Stoke-on-Trent, UK) was used to 
adhere the e-PTFE membrane to the bone. 
Table 4.1 outlines the treatment of the eight groups investigated, which were rotated 
clockwise in each successive animal to enable site dependent effects of the treatment to 
be evaluated. Cells were administered as described in Chapter 1 via incorporation 
within fibrin glue and sprayed onto the surface of the unthreaded, HA-coated segment 
(3mm diameter half of the 25 mm screw, see section 4.2.2) of the implant at 1.0 
atmosphere of pressure.  
Left tibia (no-PTFE) Right tibia (PTFE) 
Fibrin only Fibrin only 
1.0 X 10
5 
auto BMSC/ml in fibrin 1.0 X 10
5 
auto BMSC/ml in fibrin 
10 X 10
6 
auto BMSC/ml in fibrin 10 X 10
6 
auto BMSC/ml in fibrin 
10 X 10
6 
auto BMSC/ml ( in 
osteogenic media)  in fibrin 
(ogBMSC) 
10 X 10
6 
auto BMSC/ml (in osteogenic 
media) in fibrin (og BMSC) 
 
Table 4.1 The four groups used in the experiment; in the order they were placed in the first sheep. 
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4.2.4 Preparation of BMSC in Fibrin Glue 
Tiseel fibrin glue (Baxter Health care Ltd, Newbury, Berkshire, UK) was reconstituted 
at 37°C as described in Chapter 2. Preoperatively, for cell-loaded implants, 5 x 10
4
 or 5 
x 10
6
 caprine BMSC were counted and put into a universal container and spun in a 
centrifuge at 2000 rpm for 5 minutes. The supernatant was discarded and the pellet at 
the bottom of the universal container resuspended into 0.25 ml of reconstituted 
thrombin. This was mixed with 0.25ml of the Tiseel fibrinogen component 
preoperatively when the fibrin –cell mixture was sprayed onto the implants. The fibrin 
control group consisted of fibrin glue only, without cells. 
 
4.2.5 Surgical Procedure 
All animals were handled and cared for as described in Chapter 3 (materials and 
methods), and the site of surgery prepared as previously described. Four skeletally 
mature sannan goats were used in this experiment.  
Approximately six weeks prior to surgery, bone marrow aspirates were taken from goats 
in the BMSC group and BMSC isolated as outlined in Chapter 2 of this thesis. For 
inserting the tibial pins, the animal was draped to expose the medial anterior aspect of 
the right tibia. This area was rinsed with a chlorhexidine solution and a small (10.0 mm) 
incision was made 30.0 mm distal to the tibial tuberosity. The tibia was exposed by 
blunt dissection. A small section of the periosteum was scraped at the approximate 
vertical centre of the bone. A 6.0 mm hole was then drilled into the near cortex. A drill 
guide was inserted to centralise drilling. A 4.0 mm hole was drilled through the far 
cortex and tapped with an M5 tap and corresponding tap guide. The site was then 
washed with saline. At this point, implants in the treated groups were sprayed with 
fibrin with or without BMSC, according to the experimental group, onto the HA-coated 
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section of the implant with 1.0 atm of pressurised air. The implant was then inserted 
into the tibia and the threaded section screwed into the far cortex. As the implant was 
only 3.0 mm in diameter at the near cortex, there was a 1.5 mm gap between the implant 
and bone, which was bridged by the sprayed solution of fibrin with or without BMSC. 
On the right tibia, the top of the implant at the near cortex was routinely sealed with a 
square piece of e-polytetrafluoroethylene membrane (e-PTFE, Gore-Tex- Gore, 
Flagstaff, Arizona, USA) measuring approximately 5.0 mm x 5.0 mm, and glued onto 
the bone using butyl-cyanoacrylate glue (Vetbond™, National Veterinary Supplies. 
Talke Pits, Stoke-on-Trent, UK), after which, the fascia, muscle, and skin were sutured. 
Four more implants were similarly inserted in each tibia, with each implant 30 mm 
apart. 
A spray bandage (Opsite, Smith & Nephew, Gallows Hill, Warwick, UK) was applied, 
before the animal was brought out of anaesthesia. All animals received 100 mg of 
Ceftifur antibiotic as routine prophylaxis once a day for 3 days. Animals were sacrificed 
6 weeks after the procedure by intravenous injection of 0.7 mg/kg pentabarbitone (20 % 
JM Loveridge Ltd., Southampton, UK). Both tibiae were harvested immediately and 
fixed in 10% neutral buffered formalin (NBF) and processed for histology.  
 
4.2.6 Undecalcified Hard Resin Histology and Analysis 
Tibiae were prepared for histology as described in Chapter 3. A band saw was used to 
cut out approximately 20 mm sections of bone around each screw site from the tibiae, to 
facilitate processing and sectioning. Thin sections were prepared as previously 
described (Chapter 3, section 3.2.9) and bone area within the defect and bone-implant 
contact quantified using image analysis techniques. 
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4.2.7 Statistical analysis   
To test the normality of the distribution of the data, the Kolmogorov-Smimov test was 
performed, using SPSS 11.0 for Mac OSX. Non-parametric data was analysed using an 
analysis of variance (Friedman-s test) for non-parametric related samples. Data from the 
different groups were compared in pairs using the Mann Whitney U test. Results were 
considered significant when p< 0.05. 
 
4.3 Results  
 
Goats fully recovered within a few days post-operatively, and were weight bearing on 
all four limbs. 
 
4.3.1 Histology  
New Bone Formation  
Effect of ePTFE:  
Using e-PTFE membrane increased the bone formation at both low BMSC 
concentration (1.0 x 10
5 
BMSC/ml, 61.32 ± 6.94 %) and high BMSC concentration (10 
X 10
6 
BMSC/ml, 57.46 ± 4.39 %). This was statistically significant when compared to 
the group where no PTFE was used (1.0 X 10
5 
BMSC/ml, 30.76 ± 9.43 %) and (10 X 
10
6 
BMSC/ml, 28.27 ± 14.64 %) with a p value of 0.03 and 0.05 respectively.  
In the fibrin only groups and the group where BMSC were pre-treated in osteogenic 
supplemented media, presence (fibrin, 61.80 ± 5.6; Og 10 x 10
6 
BMSC, 54.84 ± 3.98) or 
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absence (fibrin, 48.91 ± 9.21; Og 10 x 10
6 
BMSC, 45.88 ± 14.7) of e-PTFE did not 
significantly increase new bone formation (p= 0.27 and 0.58 respectively).  
Effect of varying cell dose: 
No significant difference was noted in bone formation between 1x10
5
 BMSC (30.76 
± 9.43%) and 10x10
6 
BMSC (28.27 ± 14.64%). 
Effect of osteogenic differentiation of BMSC:  
Osteogenic differentiated 10x10
6 
BMSC (45.88 ± 14.7%) produced more bone than 
undifferentiated 10x10
6 
BMSC (28.27 ± 14.64%). However, this difference was not 
significant when ePTFE was used (54.84 ± 3.98% in the og 10x10
6 
BMSC group vs 
57.46 ± 4.39 % in the 10x10
6 
BMSC group). 
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Figure 4.1Percentage new bone formation (y axis) in the four treatment groups (x axis) are 
compared with and without the effect of e-PTFE. Statistically significant increase in bone 
formation was noted with e-PTFE at 1x10e5 and 1x10e7 BMSC/mL, compared to no e 
 
Bone Implant contact 
New bone formation was noted at the endosteal and periosteal surfaces of the tibial 
defects. Often fibrous tissue was noted at the bone implant interface. In one sample 
treated with 1x10e5 BMSC/mL and in two cases treated with 1x10e7 BMSC/mL, bone 
implant contact was noted. The percentage bone implant contact in these samples was 
39.6%, 18.4% and 44.3% respectively. No inference could be drawn from these 
findings. 
A   
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 B 
 
 
C  
D 
 
 
Figure 4.2 Figures A, B, C&D show some typical examples of bone implant interface as seen on 
histological sections (4x magnification). The implant (screw) is seen at the bottom of the each image. 
The old cortical bone is seen at the top part of the images. 
 
Figure 4.2 A is a sample treated with fibrin only. Figure 4.2 B is a sample treated with 
1x10
5 
BMSC/mL. Figure 4.2 C is a sample treated with 1x10
7 
BMSC/mL. Figure 4.2 D 
is a sample treated with 1x10
7 
ogBMSC/mL. New bone formation is seen in all samples. 
Bone implant contact is not complete in any of these examples, with fibrous tissue noted 
at the implant interface. 
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4.4 Discussion  
 
A careful interpretation of the results in this study is crucial, considering the various 
interactions that could take place between e-PTFE, BMSC and ogBMSC and fibrin.  
The role of e-PTFE in guided bone regeneration is established by the increased bone 
regeneration noted in the e-PTFE group compared to the non e-PTFE group. This 
difference is less marked in the fibrin group and ogBMSC group. An untreated control 
was not used in this model. However, conclusions can be drawn from two previous 
studies where similar models were used. Kalia (2007) studied the same model in sheep 
and noticed the highest average new bone formation in the untreated control group. 
Bhumbra et al (1998) showed increased bone formation using e-PTFE without BMSC 
in a rabbit femur model. 
 There may be a few possible explanations for this including the fact that guided bone 
regeneration using e-PTFE is not ideal for all cell types. It may be detrimental to 
concentrate BMSC in a small defect using a semipermeable membrane. This might 
explain why the new bone formation in the no BMSC (fibrin only) group was higher 
than in the other groups. This may also explain the lack of dose-related increase in the 
new bone formation noted in the two BMSC groups; and the ogBMSC group not 
showing significantly higher bone formation compared to all other groups. The presence 
of a small defect in otherwise healthy bone should have triggered the natural bone 
remodelling process. Fibrin promotes cell proliferation and migration (Becker et al., 
2004). Tisseel contains factor XIIIa, and fibronectin, which encourages cell migration 
(Cox et al., 2004); (Brown et al., 1993), in addition to increasing levels of the 
angiogenic factor VEGF (Hojo et al., 2003). In such a situation, the presence of BMSC 
may have led to cell-cell interactions with migrated cells and perhaps inhibition of one 
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or more group of cells, reducing the overall bone formation. This may explain why the 
fibrin only group by providing a natural scaffold, enhanced optimum bone regeneration. 
It must be noted that fibrin itself is osseoinductive only in combination with 
osteoprogenitor cells such as BMSC or an osteoconductive scaffold such as 
hydroxyapatite (Abiraman et al., 2002); (Lee et al., 2005); (Yamada et al., 2003). The 
increased bone growth noted in the fibrin only group in this study is probably not a 
direct result of its osseoinductive effect, but reflects the lesser bone formation noted in 
the other groups. 
The model itself may be responsible for the pattern of results noted. While the screw 
was fixed to the far cortex, there was a 1.5mm gap between the implant and bone in the 
near cortex to load the BMSC with or without fibrin. This would allow micromotion 
when the tibia is loaded. While lower levels of micromotion are known to be beneficial 
for stimulating bone formation, higher motion can cause fibrous tissue formation (Jasty 
et al., 1997).  
One marked difference between the tibial defect model and the acetabular model 
described in Chapter 3 or rigid fixation models described by Petite, et al. (2000) and 
Arinzeh, et al. (2003) is the pattern of mechanical loading of the construct. Mechanical 
load promotes proliferation and differentiation of osteoblastic precursor cells (Nagatomi 
et al., 2003), (Ignatius et al., 2005). However, the pattern of strain may decide the 
differentiation of the precursor cells along definitive cell lineages (Hamilton et al., 
2004).  
Whereas low stress and strain are conducive to intramembranous bone formation, 
compressive stresses have been shown to induce a chondrogenic response in BMSC. 
Ignatius, et al. (2005) demonstrated increasing expression of the master osteoblastic 
gene CBFA-1 after mechanical stretching of a human osteoblast precursor cell line 
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(hFOB 1.19). It has been proposed that this mechanical effect is regulated by the MAP 
kinase (MARK) signalling pathway, using extra cellular signal-regulated kinase 1/2 
(ERK 1/2) (Simmons et al., 2004).  
Thus, the cells may not have differentiated into osteoblasts or may have differentiated 
into another cell type such as a fibroblast phenotype. 
Future studies with this model must be planned carefully. It is desirable to ‘mark’ cells 
to note migration and differentiation of implanted BMSC. Using varying defect sizes 
may help establish their role of implanted cell numbers on bone formation. Analysis of 
forces acting at the defect size can explain the pattern of mechanical stress on the 
BMSC. It may also be useful to use dual energy X-ray absorptiometry (DEXA) to 
digitally monitor and quantify bone density to analyse bone formation. Further studies 
in other successful models may be ideal for determining the optimum BMSC 
concentration to promote maximum cell growth. Characterising the BMSC using cell 
markers may confirm their osteogenic differentiation potential. 
 
4.5 Conclusion 
 
In conclusion, e-PTFE seems to play a role in guided bone regeneration using BMSC. 
The fibrin only group had an overall higher bone formation, probably resulting from 
lesser bone formation in other groups. Both interactions between fibrin, BMSC, e-PTFE 
and mechanical factors related to this model are responsible for these results. Simpler 
and more carefully planned studies are recommended in order to analyse these factors in 
future when the bone defect model is used. 
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5. The Role of Differentiated Bone Marrow Stromal 
Cells in Augmenting the fixation of Massive 
EndoProsthetic Replacements 
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5.1 Introduction 
 
As discussed in Chapter 2 of this thesis, BMSC can be isolated from bone marrow 
aspirate. When cultured in osteogenic supplemented culture media, they differentiate to 
form osteogenic precursor cells that show high ALP activity and can produce deposits 
of calcium phosphate. In the previous chapter, the role of these differentiated cells in 
stimulating new bone formation was studied. However, as discussed in that chapter, due 
to the characteristics of the small defect model and the use of PTFE membrane, 
interpretation of results is difficult. Besides it is not known if varying the numbers of 
BMSC introduced into the defect site affects the ability of the differentiated stromal 
cells to promote bone formation.  
A massive endoprosthetic replacement in a sheep was the model chosen for this study. 
A similar model has previously been used to successfully demonstrate the ability of the 
BMSC to augment the fixation of this prosthesis (Kalia et al., 2006). Endoprosthetic 
replacements are increasingly used in modern surgical management of tumors of the 
extremities. In the lower limb, bone tumor replacement prosthesis has a significantly 
lower survival rate when compared to total hip replacements (Blunn et al., 2000). 
Aseptic loosening is a common cause of failure (Unwin et al., 1996); (Roberts et al., 
1991). In the absence of sufficient bone stock revisions of the original implant, due to 
aseptic loosening are not as successful as a primary replacement and sometimes 
amputation is required. Most common endoprosthesis for long bones are fixed to the 
remaining bone using an intramedullary cemented stem. Increasing the bone growth and 
osseointegration at the implant bone interface may improve the longevity of 
endoprosthetic replacements. One way that this has been achieved recently is the use of 
a grooved hydroxyapatite coated collar that is an integral part of the shaft and 
Chapter 5 
 117 
positioned at the shoulder of the implant adjacent to the transection site of the bone. A 
number of studies have shown that this encourages bone bridging and enhances the 
fixation of the implant (Whiteside and Easley, 1989); (Keaveny and Bartel, 1993).  
Unfortunately, bone bridging is not that predictable and occurs only in around 70% of 
distal femoral cases and the bone that is formed is of variable quality.  Application of 
stem cells to the HA collar may reduce the variability of bone formation.    
 
The hypotheses of this chapter are: 
1. BMSC differentiated in an osteogenic supplemented media (ogBMSC) will 
improve bone growth compared to undifferentiated BMSC 
2. A higher dose of ogBMSC will improve bone growth compared to a lower dose 
of ogBMSC.  
 
The aims and objectives of this chapter are to:  
1. Spray differentiated ogBMSC at two different concentrations (2 x 10
6
 ogBMSC and 
10 x 10
6 
ogBMSC) in fibrin glue onto the HA-coated collars of tibial midshaft 
replacements in an ovine in vivo model;  
2. Compare the area of new bone formation between undifferentiated (10x10
6
 BMSC) 
and differentiated BMSC (2 x 10
6
 ogBMSC and 10 x 10
6 
ogBMSC). 
3. Measure the area of new bone growth around the implants using radiography, and 
compare these results to implants treated with fibrin glue only.  
4. Observe and measure the area of bone growth around each implant collar using 
histological techniques.  
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5. Measure the bone-implant contact of each implant collar.  
 
5.2  Materials and Methods 
 
Experimental model: Skeletally mature (65-85kg) English mules were selected as the 
animal model for this study. All animals were cared for as described in Chapter 2 
(Materials & Methods). 
 
5.2.1 BMSC Isolation and Expansion 
BMSC were isolated as previously described (See Chapter 2, section 2.2.5 Materials 
and Methods). In all cases cells were expanded to passages 3 and 4 for use in this study.  
 
5.2.2  Experimental Groups  
There were four experimental groups, with six animals randomly assigned to each:  
Group 1: Implants sprayed with 2 ml fibrin glue/collar. 
Group 2: Implants sprayed with 10 x 10
6
 autologous BMSC/collar in 2 ml fibrin glue. 
Group 3: Implants sprayed with 2 x 10
6
 osteogenic autologous BMSC/collar in 2 ml 
fibrin glue. 
Group 4: Implants sprayed with 10 x 10
6
 osteogenic autologous BMSC/collar in 2 ml 
fibrin glue. 
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5.2.3  Preparation of BMSC in Fibrin Glue  
The fibrin glue used was Tisseel
®
 fibrin glue (Baxter Health Care Ltd., Newbury, 
Berkshire, UK). This glue consisted of four components, a vapour-heated Tisseel
®
 
powder component (100-130 mg protein, of which approximately 75-115 mg is 
fibrinogen); a bovine aprotinin solution: a vapour-heated thrombin powder (45-55 mg 
protein containing about 500 IU
2
 active thrombin), and a calcium chloride solution (see 
Chapter 2 for a detailed description of fibrin's properties). The Tisseel
®
 fibrinogen 
component was reconstituted in the aprotinin solution after a 10-minute incubation at 
37°C in a heater manufactured by Baxter Health Care (Fibrinotherm
®
, Baxter Health 
Care Ltd., Newbury, Berkshire, UK). Pre-operatively, for cell-loaded implants, the 
BMSC were centrifuged at 2000 rpm for 5 minutes. The supernatant was discarded and 
the pellet at the bottom of the universal container was re-suspended in the 1 ml of 
reconstituted thrombin and injected back into the manufacturer's vial for transport to the 
operating theatre.  
 
5.2.4 Implant Design and Manufacture  
The implant used was a mid-shaft tibial replacement, which was a design that had 
previously been used in a goat in vivo study by (Kalia, 2007) and Coathup, et al. (2000). 
Implants were made from titanium alloy (T16A14V). The implant shaft was 50 mm 
long and 10 mm in diameter. HA-coated collars were used at each transection site. HA 
coatings were highly crystalline and were around 50 µm thick (Plasma Biotal, 
Tideswell, North Derbyshire, UK). The collars were 15 mm in length, with 1 mm 
grooves. The implant consisted of proximal and distal parts that were joined together 
during surgery by two juxtapositioned screws. Each stem was fixed within the 
intramedullary canal using cement. A long groove was present along each stem to 
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promote the interlocking of cement (Figure 5.1).  
 
Figure 5.1 Titanium mid shaft tibial endoprosthesis with HA coated collars 
 
5.2.5 Surgical Procedure 
All animals were handled and cared for as described in Chapter 2 (Materials and 
Methods) and the site of surgery was prepared as previously described. Approximately 
six weeks prior to surgery, bone marrow aspirates were taken from skeletally mature 
mule ewes, from the appropriate experimental animals and BMSC isolated as outlined 
in Chapter 2 of this thesis.  
For implantation of the tibial massive endoprosthesis, tibiae were first clipped to expose 
the skin, after which the area was washed with an iodine solution (as described in 
Chapter 2). The operation was carried out under sterile conditions. The animal’s right 
leg was draped to expose the medial anterior aspect of the right tibia. This area was 
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rinsed with a chlorhexidine solution and then a proximal-distal incision 60 mm in length 
was made, starting 50 mm distal to the tibial tuberosity. A 50 mm section of the tibial 
midshaft was excised 60 mm from the tibial tuberosity using an air-saw. The periosteum 
from this section was removed intact.  
Intramedullary canals were prepared for implantation by first removing the bone 
marrow, then by repeated washing with saline (a sterile, 0.9% sodium chloride 
solution). Where necessary, canal diameters were increased to ensure a minimum 
cement mantle thickness of approximately 1.5 - 2.0 mm. In experimental group animals, 
2 mL of autologous BMSC in fibrin glue was sprayed onto the HA-coated surface of the 
implant collars (proximal and distal) at 1.0 atm of pressure. To do this, the fibrinogen 
and thrombin components of the fibrin glue were transported to the operating theatre 
with or without BMSC and maintained at 37° C in a Baxter Fibrinotherm
®
 device 
(Baxter Health Care Ltd., Newbury, Berkshire, UK) until used. Each component was 
loaded into a 1.0 mL syringe (included in the Tisseel
®
 package) and snapped into a 
dual-syringe holder with attached plunger device. To spray the fibrin glue using this 
system, a Duploject
®
 (Baxter Health Care Ltd., Newbury, Berkshire, UK) spray set was 
used, which consisted of sterile plastic tubing which connected to a dual-syringe tip, 
which allowed air to come into contact with the fibrin components as they came out of 
the syringe. The other end of the tubing was connected to a Fibrijet
®
 (Micromedics, 
Inc., St. Paul, Minnesota, USA) pressure gauge, which was connected to a pressure 
pump. The Fibrijet was set to 1 atm and the plungers of the fibrin system pressed to 
allow release of aerolised fibrin onto the surface of the HA-coated implant collars. The 
implants were slowly turned as the fibrin was applied to allow an even distribution of 
fibrin around the collar. In the BMSC groups, the corresponding concentration of cells 
was applied to each collar (proximal and distal) of every implant. Control animals 
received fibrin glue only or no treatment at all to the collar. Implants were cemented in 
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place using Palacos R cement with Gentamicin (Biomet Europe, South Wales, UK). The 
two halves of the prosthesis were joined centrally, and the surrounding fascia, muscle 
and skin were closed. 
A spray bandage (OpSite
®
, Smith & Nephew, Gallows Hill, Warwick, UK) was applied 
prior to recovery. Animals were allowed immediate postoperative mobilisation and 
weight-bearing as tolerated. Antibiotic and analgesic prophylaxis was administered 
daily with subcutaneous injections of Exenel™ (ceftiofur hydrochloride, 1 mL/50 kg, 
Pfizer Animal Health, Tadworth, Surrey, UK) and IM injections of Vetergesic™ 
(buprenorpine, 0.6 mg/animal, Reckitt and Colman Products Ltd., Hull, UK) for three 
days post-operatively. Animals were kept in individual pens until fully weight-bearing 
and were then grouped together in large pens.  
Animals were euthanised 6 months post-operatively by an intravenous overdose of 0.7 
mg/kg pentabarbitone (20, J.M. Loveridge Ltd., Southampton, UK). 
 
5.2.6 Radiography and Radiographic Analysis  
Medio-lateral (ML) radiographs of the right tibiae were taken at six months post- 
operatively for the fibrin control and the BMSC treated groups, using an MX4 X-ray 
machine (PLH Medical Ltd., Watford, UK). For analysis of new bone formation, digital 
images of the radiographs were captured using a JVC KY F55B Colour Video Camera 
using Zeiss KS300 software (Imaging Associates, Thame, UK). The radiographed area 
adjacent to the implants was divided into eight regions of equal size, and labelled from 
A to H. Images were captured using a JVC KY F55B Colour Video Camera along with 
Zeiss KS300 software (Imaging Associates, Thame, UK). Bone area in these regions 
was then quantified using the KS300 image analysis software.  
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5.2.7 Histology and Analysis 
Following sacrifice, all right tibiae were prepared for histology by stripping excess soft 
tissue and fixing in 10% neutral buffered formalin (NBF) for a minimum period of one 
week. Specimens were dehydrated in increasing concentrations of industrial methylated 
spirit (IMS). Samples were de-fatted in chloroform and immersed in a 50% IMS, 50% 
resin mixture (LR White Resin, London Resin Company Ltd., Reading, Berkshire, UK), 
followed by immersion in 100% resin. Samples were then cast using a polymerisation 
accelerator (LR J White Accelerator, London Resin Company Ltd., Reading, Berkshire, 
UK). Specimen blocks were sectioned at four sites using a water-cooled band saw with 
a diamond-edged blade (Exact saw, Germany). One section was made through the 
centre of the proximal collar and one through the centre of the distal collar. Thin 
sections (approximately 80 µm thick) were prepared (Exact grinding machine, 
Germany; and Exact Polishing machine, Germany) and stained with Toluidine Blue 
(Bancroft and Stevens, 1986) and Paragon (Tanzer, et al., 2003) to stain soft tissue and 
bone, respectively. Stained slides were then viewed under an Olympus light microscope 
and images digitally captured using a JVC KY F55B Colour Video camera. Bone area 
and bone-implant contact was quantified using image analysis software (Zeiss KS300 
software, Imaging Associates, Thame, UK). 
 
Bone Area 
To measure bone area using image analysis software, the area of bone was ‘encircled’ 
using freeform polygons and the area within it was calculated in mm
2 
by the image 
analysis software. 
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Bone-Implant Contact 
To measure the presence of bone-implant contact, 48 equi-distant points spanning the 
entire surface of the implant collar were analysed at 2.5 x magnification. The results 
were recorded as yes or no (0 or 1) at all points and the percentage of contact noted. 
 
5.2.8 Statistics 
To test normality of the distribution of the data, the Kolomgorov-Smirnov test was used, 
using SPSS 11.0 for windows. Parametric data was analysed using an independent-
samples T-test; non-parametric data was analysed using the Mann-Whitney U test. 
Results were considered significant when p < 0.05. 
 
5.3 Results 
 
Sheep fully recovered within a few days post-operatively and were weight-bearing on 
all four limbs for the duration of the experiment. 
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5.3.1  Radiology 
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Figure 5.2 Radiographic results of medio-lateral versus antero-posterior bone growth in the study 
groups 
 
There were distinct patterns of growth observed around the implants. The largest 
amount of bone was observed posteriorly and medially along the implant shaft. A 
greater amount of bone growth adjacent to the implants was observed at the proximal 
transection site than distally. The greater amount of new bone formation could be seen 
in the two BMSC-treated groups (10xl0
6
 BMSC and 10x10
6
ogBMSC/collar) compared 
to the control fibrin glue-treated groups and the low dose ogBMSC (2x10
6 
ogBMSC) 
group.  
 Bone Area 
  ML Area  SE AP Area  SE 
Fibrin Control 46.84 18.81 35.16 13.39 
10 x 10e6 oBMSC + fibrin 
glue/collar 92.57 28.94 56.94 34.69 
2 x 10e6 OBs + fibrin glue/collar 45.75 20.27 34.87 10.81 
10 x 10e6 OBs + fibrin glue/collar 47.68 18.08 73.42 29.04 
 
Table 5.1 Table depicting the average area of bone formation seen on AP and ML plain 
radiographs at 6 months. 
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 The area of new bone formation in the four study groups is summarized in Table 5.1. 
The highest increase in new bone formation was noted in the 10x10
6
 BMSC group on 
the ML view and the 10x10
6
 ogBMSC group on the AP view. Compared to the fibrin 
glue group the results were not statistically significant in any of the BMSC groups. 
 
5.3.2  Histological Analysis  
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Figure 5.3 Graph showing the area of new bone formation in the four experimental groups. 
 
In all four groups, both woven and lamellar bone was observed in and around the collars 
of the implants. The fibrin only control group was noted to have a layer of fibrous tissue 
directly in contact with the implant in most cases. In the BMSC treated groups, greater 
bone and lesser fibrous tissue were routinely noted. The mean area of new bone 
formation was noted to be highest in the high dose (10x10
6
) ogBMSC group (112.67 ± 
30.75 mm
2
), followed by the low dose (2x10
6
) ogBMSC group (mean 76.84 ± 2.25 
mm
2
) and finally the high dose (10x10
6
) BMSC group (mean 58.22± 17.22 mm
2
). 
Chapter 5 
 127 
Compared to the fibrin treated group (mean 11.24 ± 4.75 mm
2
), a significant increase in 
bone area was noted in histological sections taken at the mid point of the implant collars 
in the high dose BMSC group (mean 58.22± 17.22 mm
2 
;p = 0.02) and the high dose 
ogBMSC group (mean 112.67 ± 30.75 mm
2 
; p = 0.01). A greater area of bone 
formation was noted in the low dose ogBMSC group (mean 76.84 ± 2.25 mm
2
). 
However, compared to the fibrin only control group, the difference in bone area was not 
statistically significant (p= 0.3). Comparison of the groups treated with BMSC showed 
a statistically significant increase in the ogBMSC group compared to the high dose 
BMSC group (p= 0.02). However, no statistical significance was noted in the area of 
new bone formation between the high dose BMSC and low dose ogBMSC (p=0.7) or 
the high and low dose ogBMSC (p=0.26).  
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Figure 5.4 Graph comparing proximal and distal bone area in the four study groups 
 
Comparison of the area of new bone formation around the implant collar showed no 
significant difference between the proximal and distal collars of the implants in any of 
the study groups. The mean bone area, standard error of the mean and the p values are 
summarized in Table 5.2.  
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 Mean area in mm
2 
SE of mean
 
P value 
Fibrin – proximal 
collar 
16.89 6.11  
Fibrin – distal collar 11.2 9.66 0.67 
10x10
6 
BMSC
 – 
proximal collar 
47.26 16.51  
10x10
6 
BMSC – 
distal collar 
65.52 29.32 0.63 
2x10
6 
ogBMSC – 
proximal collar 
100.30 21.32  
2x10
6 
ogBMSC – 
distal collar 
61.21 46.93 0.50 
10x10
6 
ogBMSC – 
proximal collar 
95.65 67.88  
10x10
6 
ogBMSC – 
distal collar 
95.41 32.61 0.98 
 
Table 5.2 Comparison of proximal and distal collars in the four study groups 
 
Bone - Implant Contact 
The average bone-implant contact was noted to be 17.18% (± 7.93) in the 10x10
6 
BMSC group, 27.78% (± 10.23) in the 2x10
6 
og BMSC group and 28.13% (± 18.33) in 
the 10x10
6 
og BMSC group. The bone-implant contact was not found to be statistically 
different (p value of 0.4, 0.8 and 0.9 respectively) in any of the above BMSC treated 
groups compared to the fibrin only control group (21.58% ± 9.67). 
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5.4 Discussion  
 
My study has demonstrated that BMSC, when sprayed onto the surface of HA-coated 
implant collars, significantly increased bone formation around the collars and improved 
bone-implant contact to massive segmental bone tumour implants. Differentiating 
BMSC in osteogenic supplemented media further increased the total area of new bone 
formation. Promoting the growth of bone at the collar of the massive implants will aid 
in load transfer between the bone and implant. This may improve the longevity of 
fixation of the implant.  
Radiographic analysis of bone growth in all groups indicated a similar pattern, whereby 
there was more new bone formation medially and posteriorly around the implants and 
less new bone formation laterally and anteriorly. This pattern is similar to that observed 
in humans with femoral endoprosthetic replacements, where medial and posterior 
increases in bone mineral density (BMD) was found to be accompanied by a decrease 
Figure 5.5 Histological sections of bone implant junction. HA-coated implant collars showed 
increased bone formation (left) compared to fibrin sprayed implant collars (right) 
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laterally and anteriorly (Inglis and Walker, 1991). This reflects the pattern of stress and 
strain around proximal femoral replacements measured telemetrically (Taylor et al., 
1997) and a study using photoelastic coatings to measure shear strain (Hua and Walker, 
1992), where the strain measured medially was 53% of normal on the medial side, but 
only 35% on the lateral side of the implant.  
 In my study radiological analysis showed an increase in bone formation in all groups at 
6 months. The highest increase in new bone formation was noted in the 10x10
6
 BMSC 
group in the ML view and the 10x10
6
 ogBMSC group in the AP view. However, no 
statistical difference was noted between the fibrin treated and BMSC treated groups. It 
is possible that plain radiographs were not sensitive to detect new bone formation. In 
future studies it may be possible to accurately detect new bone formation by using 
sensitive radiological tools such as three-dimensional reconstruction of multiple thin 
section computer tomography. 
Histological analysis of the mid section of the massive implants showed an increased 
area of new bone formation in all the BMSC treated groups compared to the fibrin only 
group. This confirms the role of BMSC in promoting new bone formation.  A 
statistically significant increase in new bone formation was noted in the high dose 
BMSC group and the high dose osteogenic supplemented BMSC group compared to the 
fibrin only group. In the low dose osteogenic supplemented BMSC group, there was no 
statistically significant increase in bone growth compared to the fibrin only group.  It is 
possible that the beneficial effect of BMSC and the osteogenic supplemented BMSC 
groups is only seen above a certain cell concentration.  Whether the higher cell 
concentration used in my study was optimal for bone formation, could not be 
determined from my investigation.    My study also shows that, the increase in bone 
growth can be further improved by differentiating the BMSC in an osteogenic 
supplemented media.  
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Massive endoprosthesis are currently in clinical use. This model has obvious advantages 
in terms of immediate weight bearing mobilization. Fibrin glue is a convenient vector 
for BMSC as it is commercially available and simple to reconstitute and assemble. 
BMSC have also been studied in rats when combined with a gel carrier (Lee et al., 
2005), or when seeded in an osteoconductive surface such as ß-tricalcium phosphate or 
HA, in conjunction with an internal plate (Arinzeh et al., 2003), external distraction 
(Richards et al., 1999) or external fixation (Lee et al., 2005). It is possible that 
osteoinduction could be further encouraged by using a scaffold that promotes the 
proliferation of cells and their differentiation into osteoblasts, as well as retaining them 
in the structure. An example of this could be fibrin combined with BMPs, HA or ß-tri-
calcium phosphate, or all of these combined (Hong et al., 2006), (Han et al., 2005); 
(Schmoekel et al., 2005). 
It has been suggested that fibrin glue can have a pro-angiogenic effect, which may 
promote new bone growth or repair (Kania et al., 1998). It is possible that in this study 
fibrin played some role in increasing bone formation in the fibrin-only control group. 
However, all the BMSC treated groups in this study have shown a higher average new 
bone formation above the fibrin treated group. This provides evidence for the bone 
promoting role of BMSC. 
HA has already been well documented in the literature as being osteoconductive (Blunn 
et al., 2000); (Coathup et al., 2000); (D'Antonio et al., 1992), (D'Antonio et al., 1992, 
Geesink, 1993). Possible mechanisms of this bone-promoting effect have been 
suggested. One theory is that as HA slowly degrades in the body, the degradation 
products released from the implant surface, such as calcium and phosphate, or the 
change in pH (Ozawa and Kasugai, 1996); (Kurioka et al., 1999) may promote 
differentiation of the BMSC to osteoblasts, or even improve bone formation by host 
osteoblasts which have migrated to the implant site, or the BMSC-derived osteoblasts 
Chapter 5 
 132 
(Datta et al., 2006). Kilpadi, Chang and Bellis (2001) have also shown that HA has the 
capacity to bind proteins such as important integrins (for example a5ßl and avß3), as 
well as fibronectin, vitronectin and osteoblast precursor cells, when compared to metals. 
Integration of an implant into the bone shaft is important for better load transfer to the 
bone shaft and off-loading the implant stem, which may reduce loosening of the 
implant. In patients with thin stems, this may reduce mechanical failure. This may be 
important in younger patients, where a relatively small implant is inserted. The 
osseointegration of the implant may allow these implants to survive into adulthood.  
 
 
 
 
 
 
 
 
 
 
 
One drawback of using autologous BMSC in a patient with a malignant bone tumor is 
the theoretical question of whether the isolated BMSC have metastatic cells. The 
clinical solution to this would be to use allogenic BMSC (Horowitz et al., 1993).  
age 19 
Duration   
12 years 3 
months  
 Age  21 years Duration  5 years 8 
months   
Figure 5.6 Radiograph of a patient with a relatively thin stem inserted 
when the bone was still growing. The incorporation of the HA has 
probably protected the implant from loosening and fracture despite 
the relative bone growth. 
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5.5 Conclusion 
 
In conclusion, in an in vivo massive endoprosthesis model, 10x10
6
 BMSC increases the 
area of new bone formation. This can be further increased by treating the BMSC in an 
osteogenic supplemented media.  
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My thesis confirms that BMSC suspended in fibrin glue can be sprayed onto the surface 
of orthopaedic implants to improve osseointegration by promoting new bone formation 
adjacent to the implants and decreasing fibrous tissue in contact with the implants. The 
hypothesis has been tested in three different implant models – a goat acetabular cup 
model; a sheep tibial pin model and a sheep massive tibial endoprosthesis model.  
 
Chapter 2 describes the technique of isolating BMSC from iliac crest aspirate. Cells 
were expanded in culture. The cells were characterised by differentiating them down 
different cell lineages (osteoblastic, chondrogenic and adipogenic), using chemical cues. 
In order to fully characterise the oBMSC used in this study and identify them as being 
the multipotent cells described in the literature (Haynesworth et al., 1992); (Jaiswal et 
al., 1997), more in vitro work needs to be done looking at gene expression after 
stimulation with supplements for differentiation. Also, surface marker analysis needs to 
be carried out, with a panel of antigens that are known to positively or negatively react 
with BMSC, using a FACS or MACS system (Pittenger et al., 1999).  
BMSC are thought to undergo osteogenic differentiation via a MAP kinase-mediated 
mechanism (Jaiswal et al., 2000). Pre-differentiation of these cells into osteoblast 
precursor cells or osteoblasts may help expedite the bone healing process by skipping 
stages of differentiation, or the requirement for certain environmental/mechanical cues  
in order to differentiate and, once integrated into the repair site, could begin to produce 
bone matrix and matrix mineralisation without delay. Additionally, the applied cells 
could be genetically modified to express osteogenic growth factors and cytokines. 
Also described in Chapter 2 is the technique of coating the implant surface with BMSC 
prior to implantation. The viability, proliferation, and morphology of BMSC did not 
alter in vitro after being sprayed at 1 atm with fibrin glue. The advantage of using this 
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technique is the ability to intra operatively spray the implants with the BMSC-fibrin 
glue mixture. The use of such a system would be a much more convenient and 
translatable method, as the cells are cultured separately and then combined with fibrin 
per-operatively rather than pre-culture of the cells onto the implant. Pre-sterilised 
implants of any desired type can be used and there is no handling of implants before the 
intended procedure.  Studies comparing ceramic cubes seeded with stem cells and then 
cultured  with similar cubes where the cells were incorporated at the time of surgery 
showed that there was no difference in bone formation when the cubes were implanted 
in an ectopic site (Kruyt et al., 2004).  
The ability of BMSC to improve bone implant contact was investigated in Chapter 3. A 
goat (in vivo) total hip arthroplasty model was used in this study. Culture expanded 
BMSC (10x10
6
 cells) suspended in fibrin glue was sprayed on the surface of 
hydroxyapatite-coated press-fit acetabular cups and this was compared to fibrin only 
sprayed control groups. The area of new bone formation adjacent to the implants was 
increased when implants were treated with BMSC in fibrin glue when compared to 
fibrin only treated implants. Overall a 30% increase in new bone formation was noted 
when acetabular cups were treated with BMSC. Along the surface of the cup, the 
contact between bone and the implant was noted to be increased when cups were 
sprayed with BMSC. This increase was statistically significant at the periphery of the 
cups (p=0.014). Additionally, the BMSC treated surface also decreased the fibrous 
tissue in immediate contact with the implant, with a statistical difference noted at the 
periphery of the cup (p = 0.09). It is important to note that no difference in loading was 
observed between the study and control groups in any of the animals. The exact reason 
for statistically significant improvement in bone-implant contact at the periphery of the 
cup compared to the central portion of the cup is not clear. As outlined in the discussion 
section of Chapter 3, it is possibly a combination of factors including differential 
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loading at various points on the cup surface, cell migration and differentiation. Further 
studies using markers to track the cells and close measurement of forces across various 
points of the implant-bone construct may provide useful information regarding this 
phenomenon. Radiological imaging using radioisosteriometry (RSA) may be another 
useful measure of implant migration and its consequence on osseointegration.   
In Chapter 3, a primary hip arthroplasty scenario was investigated. It would be 
beneficial to apply this principle in a revision hip arthroplasty scenario. At revision hip 
arthroplasty there is less available bone stock due to lysis. In this situation, implants 
coated with stem cells and fibrin glue may allow the stem cells to concentrate in the 
bone defects at the implant interface. In addition, if bone grafting is necessary for 
structural support during revision arthroplasty surgery, stem cells may be used along 
with the morselised bone graft.  
Following on from the results of Chapter 4, another large animal in vivo model was 
used in order to establish if varying cell doses; differentiating BMSC using osteogenic 
supplements or concentrating the cells using an artificial semi-permeable membrane (e-
PTFE) effects bone formation. Four groups (with or without e-PTFE) were tested in 
Chapter 4, fibrin only, 1.0x10
5
 BMSC,  10x10
6
 BMSC and 10x10
6
 osteogenic 
supplemented BMSC, forming a total of eight experimental groups. HA-coated 
transcortical screws were coated with one of the eight treatments, and implanted into 
1.5mm tibial gaps in the mid-shaft of sheep. After a period of six months, bone 
formation, and bone-implant contact was assessed histologically. Using e-PTFE 
statistically increased bone formation in low and high BMSC group (p= 0.03 and 0.05 
respectively) but not in the osteogenic supplemented BMSC group. Overall, no 
significant increase in bone formation was noted in any of the groups compared to the 
fibrin-only control group. One of the salient features responsible for the pattern of 
results noted in this study is the lack of cell loading in the tibial defect – pin model. 
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This, along with the absence of an untreated control group and complex interactions 
between the fibrin, BMSC and e-PTFE make interpretation of the results of this 
experiment difficult.  
Chapter 5 investigated the ability of BMSC to augment new bone formation adjacent to 
massive orthopaedic implants in an ovine model. The effect of osteogenic 
supplementation of different cells doses of BMSC was also investigated. Once again, 
fibrin sprayed control groups were used as controls to test 10x10
6
 BMSC, 2x10
6
 
osteogenic supplemented BMSC and 10x10
6 
osteogenic supplemented BMSC sprayed 
on the collars of massive tibial endoprosthesis. The area of bone adjacent to the 
implants and to the implant collars was increased when implants were treated with low 
and high doses of oBMSC in fibrin glue when compared to fibrin treated implants. 
Increasingly greater bone formation was noted with 10x10
6 
BMSC, 2x10
6 
osteogenic 
supplemented BMSC and 10x10
6
 osteogenic supplemented BMSC respectively. 
However, the results were found to be statistically significant in the 10x10
6 
BMSC 
(p=0.02) and the 10x10
6
 osteogenic supplemented BMSC (p=0.01). Those implants 
treated with a higher density of differentiated cells showed an increase in new bone 
formation when compared to those treated with the lower number of cells. Compared to 
fibrin treated groups, no increase in bone implant contact was seen in any of the BMSC 
treated groups. It is possible that fibrin acted as a scaffold and promoted migration and 
concentration of osteoblasts at the implant collar. A comparison group with untreated 
implants would have further highlighted this aspect.  
Summary of the results of all chapters 
1) Autologous BMSC can be isolated from BM aspirate and expanded along the 
osteogenic pathway. They can be sprayed on to the surface of orthopaedic implants 
intra-operatively without affecting cell viability, metabolism or proliferation. 
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2) Bone formation was higher with osteogenic 10x106 BMSC (112.67 ± 30.75 
mm
2
) compared to osteogenic 2x10
6 
BMSC (76.84 ± 2.25 mm
2
). No significant 
difference was noted in bone formation between undifferentiated 1x10
5
 BMSC 
(30.76 ± 9.43%) and undifferentiated 10x10
6 
BMSC (28.27 ± 14.64%). 
3) Osteogenic differentiated 10x106 BMSC (112.67 ± 30.75 mm2) produced more 
bone than undifferentiated 10x10
6 
BMSC (58.22 ± 17.22 mm
2
).  
4) Using semipermeable barriers resulted in significantly increased bone formation 
when undifferentiated 1x10
5
 BMSC (61.32 ± 6.94% vs 30.76 ± 9.43%) or 
undifferentiated 10x10
6 
BMSC (57.46 ± 4.39% vs 28.27 ± 14.64%) was used. 
This difference was not noted when osteogenic differentiated 10x10
6 
BMSC was 
used. 
 
6.1 Future Work 
Further progress in this research is necessary in following directions: 
1) The optimum cell concentration of BMSC has to be further established using carefully 
planned in vivo experiments. 
2) The use of allogenic BMSC in place of autologous BMSC has to be investigated. One 
must consider that when using the autologous BMSC of a bone cancer patient, there is a 
theoretical risk of undetected metastatic tumour cells being isolated from the bone 
marrow in addition to BMSC. If this is the case, use of donor-derived, allogeneic BMSC 
may also be useful (Horowitz et al., 1993). However, one must also consider that all 
BMSC, autologous or allogenic, are immunosuppressive and express VEGF, which is 
essential to tumour growth (Aggarwal and Pittenger, 2005); (Ferrara and Davis-Smyth, 
1997). These effects may have negative consequences for tumorigenesis in any patient 
(Djouad et al., 2003). 
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3) Most importantly, human clinical trials have to be conducted to establish the role of 
BMSC in augmenting the fixation of orthopaedic implants in clinical scenarios such as 
revision surgery, complicated trauma surgery and tumor surgery. Animal models do not 
always replicate complex clinical scenario. For example, during revision hip 
arthroplasty, extensive trauma or reconstruction following extensive tumor surgery, the 
surgeon is faced with the challenge of inadequate bone stock, infection and deficient 
soft tissue cover. Cost and ethical issues prevent development of a model that would 
replicate this scenario. Only human trials can provide establish the role of BMSC in 
these complex situations. 
4) In future work, cells should be tracked to try and identify their contribution to new bone 
formation in in vivo models. This could be done by genetically modifying the cells to 
express a gene, such as lacZ, which encodes the bacterial enzyme P-galactosidase, green 
fluorescent protein (GFP) and Flue, which encodes firefly luciferase (Zhou et al., 2005). 
5) A further strategy to improve bone formation around the implants could be to 
incorporate growth factors into the fibrin-cell mixture that is sprayed onto the HA 
collars. Inclusion of growth factors such as BMP-2 or BMP-7, well documented 
osteogenic factors, could further increase bone formation by influencing the 
differentiation of the cells. Alternatively, these factors could be supplied using a cell 
therapy approach, where genetically modified BMSC, expressing BMPs or other 
relevant genes, could be implanted at the repair site (Tsuchida et al., 2003); (Lieberman 
et al., 1999); (Edwards et al., 2005); (Mistry and Mikos, 2005). Growth factors targeting 
neo-angiogenesis and revascularisation could also play an important role, such as VEGF 
(Geiger et al., 2005); (Peng et al., 2005) and SDF-1.  
6) In a clinical trial, robust clinical outcome measurements are prudent to demonstrate any 
increase in bone formation compared to controls. Implant migration measured using 
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radiostereometric analysis (RSA) may be the ideal primary outcome measure. 
Secondary outcome measures that can be employed may be bone density measurements 
adjacent to the implant as quantified using DEXA scanning, radiological assessment 
investigating and quantifying signs of implant loosening and function of the hip; that is, 
pain-free mobility as assessed using a Harris Hip Score.  
7) BMSC were used in the in vivo models in this study, rather than peripheral bone 
marrow stromal cells (PBSCs). BMSC have been used in other models previously, but 
there is only one other described study in the literature utilising PBSCs (Wan et al., 
2006). Most literature on PBSCs (Rochefort et al., 2006); (Mansilla et al., 2006); 
(Khosla and Eghbali-Fatourechi, 2006); (Kassis et al., 2006) have been published 
relatively recently, although they show a similar potential for use in bone tissue 
engineering applications as BMSC (Wan et al., 2006).  
 
In conclusion, viable BMSC can be successfully isolated from bone marrow aspiration, 
differentiated along the osteogenic pathway and sprayed on the surface of various 
orthopaedic implants to improve bone-implant contact. This may be an ideal alternative 
to improve osseointegration of implants in challenging clinical scenarios with deficient 
bone stock. Moreover, this research may pave the way for further advances in tissue 
bioengineering such as the use of allogenic cells in immunodeficient individuals 
undergoing orthopaedic replacement procedures or the use of cells in combination with 
BMPs to enhance implant fixation. It is crucial to test the results of these studies in 
various clinical scenarios by using carefully planned blinded randomized control trials. 
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